METHYLPREDNISOLONE ( DrugBank: Methylprednisolone )

46 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	1
11	重症筋無力症	3
13	多発性硬化症／視神経脊髄炎	58
14	慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー	2
18	脊髄小脳変性症（多系統萎縮症を除く。）	1
19	ライソゾーム病	2
25	進行性多巣性白質脳症	2
26	HTLV-1関連脊髄症	2
35	天疱瘡	1
38	スティーヴンス・ジョンソン症候群	1
39	中毒性表皮壊死症	1
40	高安動脈炎	1
41	巨細胞性動脈炎	1
42	結節性多発動脈炎	2
43	顕微鏡的多発血管炎	4
45	好酸球性多発血管炎性肉芽腫症	2
46	悪性関節リウマチ	37
49	全身性エリテマトーデス	17
50	皮膚筋炎／多発性筋炎	12
51	全身性強皮症	10
60	再生不良性貧血	13
62	発作性夜間ヘモグロビン尿症	1
63	特発性血小板減少性紫斑病	2
64	血栓性血小板減少性紫斑病	1
65	原発性免疫不全症候群	5
66	IgA腎症	11
83	アジソン病	1
84	サルコイドーシス	1
85	特発性間質性肺炎	1
86	肺動脈性肺高血圧症	1
93	原発性胆汁性胆管炎	2
95	自己免疫性肝炎	1
96	クローン病	4
97	潰瘍性大腸炎	6
145	ウエスト症候群	1
162	類天疱瘡（後天性表皮水疱症を含む。）	3
164	眼皮膚白皮症	1
211	左心低形成症候群	1
220	急速進行性糸球体腎炎	1
222	一次性ネフローゼ症候群	9
224	紫斑病性腎炎	1
271	強直性脊椎炎	1
283	後天性赤芽球癆	1
284	ダイアモンド・ブラックファン貧血	2
285	ファンコニ貧血	7
296	胆道閉鎖症	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01884571 (ClinicalTrials.gov)	October 2013	19/6/2013	Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)	A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis (ALS)	Amyotrophic Lateral Sclerosis (ALS)	Drug: Basiliximab;Drug: Methylprednisolone;Drug: Prednisone;Drug: Tacrolimus;Drug: Mycophenolate mofetil	Emory University	ALS Association	Completed	18 Years	N/A	All	31	Phase 2	United States

11. 重症筋無力症

臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs051200137	17/02/2021	17/02/2021	Efficacy and safety of methylprednisolone pulse therapy for ocular myasthenia gravis: a pilot study	Efficacy and safety of methylprednisolone pulse therapy for ocular myasthenia gravis: a pilot study - ESPRETHO	ocular myasthenia gravis ocular myasthenia gravis, steroid pulse, methylprednisolone	Methylprednisolone 1 g daily is administered intravenously for 3 consecutive days for 2 to 3 courses, and then 5 mg of prednisolone daily is orally administered until 16 weeks.	Koh Jinsoo	NULL	Recruiting	>= 20age old	Not applicable	Both	10	N/A	Japan
2	EUCTR2019-003383-47-IT (EUCTR)	12/08/2020	25/09/2020	A Study to Investigate the Safety, Tolerability, and Efficacy of TAK-079 in Participants With Generalized Myasthenia Gravis	A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis - -	Generalized Myasthenia Gravis MedDRA version: 21.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: TAK-079 Product Code: [TAK-079, TSF-021, TSF79] INN or Proposed INN: TAK-079 Other descriptive name: TAK-079 Product Name: metilprdnisolone Product Code: [-] INN or Proposed INN: METILPREDNISOLONE Other descriptive name: methylprednisolone Product Name: difenidramina Product Code: [NA] INN or Proposed INN: DIFENIDRAMINA CLORIDRATO Other descriptive name: diphenhydramine hydrochloride Product Name: paracetamolo Product Code: [acetominofene] INN or Proposed INN: PARACETAMOLO Other descriptive name: acetaminophen	MILLENNIUM PHARMACEUTICALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	36	Phase 2	United States;Serbia;Canada;Spain;Poland;Italy
3	NCT00424489 (ClinicalTrials.gov)	February 2002	18/1/2007	Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis	Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis	Myasthenia Gravis	Biological: Hematopoietic Stem Cell Transplantation;Drug: Cyclophosphamide;Drug: ATG (rabbit);Drug: Mesna;Drug: Methylprednisolone;Drug: G-CSF	Northwestern University	NULL	Terminated	15 Years	65 Years	All	9	Phase 1	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05232825 (ClinicalTrials.gov)	May 3, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: Dexamethasone given orally;Drug: Desloratadine given orally	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	65 Years	All	234	Phase 3	United States;Australia;Brazil;Czechia;Italy;New Zealand;Poland;Spain;Turkey;Canada;Russian Federation;Ukraine
2	NCT04979650 (ClinicalTrials.gov)	May 22, 2021	2/7/2021	Corticosteroid Effects on Asymptomatic Gadolinium-enhancing Lesions in Multiple Sclerosis	Corticosteroid Pulse Therapy Effects on MRI Asymptomatic Gadolinium-enhancing Lesions Conversion to a Non-enhancing Black Hole With or Without Treatment in MS Clinic of Booalisina Hospital Sari 2021-2023	Multiple Sclerosis, Relapsing-Remitting;Magnetic Resonance Imaging;Methylprednisolone	Drug: Methylprednisolone succinate;Drug: Normal saline	Mazandaran University of Medical Sciences	NULL	Enrolling by invitation	18 Years	55 Years	All	104	Phase 2	Iran, Islamic Republic of
3	NCT04688788 (ClinicalTrials.gov)	April 28, 2021	22/12/2020	Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Danish Non-inferiority Study of Ocrelizumab and Rituximab in MS (DanNORMS): A Randomized Study Comparing the Efficacy of Ocrelizumab and Rituximab in Active Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Rituximab;Drug: Ocrelizumab;Drug: Fexofenadine;Drug: Paracetamol;Drug: Methylprednisolone	Rigshospitalet, Denmark	Odense University Hospital;Aarhus University Hospital;Aalborg University Hospital;Herlev Hospital;Hillerod Hospital, Denmark;Zealand University Hospital;Kolding Sygehus;Regional Hospital Holstebro;Hvidovre University Hospital;Hospital of South West Jutland, Esbjerg, Denmark;GCP unit, Copenhagen University Hospital;GCP-unit at Aarhus University Hospital, Aarhus, Denmark;Hospital of Southern Jutland, Sønderborg, Denmark;Hospital of Central Denmark Region, Viborg, Denmark;Danske Regioner	Recruiting	18 Years	65 Years	All	594	Phase 3	Denmark
4	NCT04548999 (ClinicalTrials.gov)	December 3, 2020	9/9/2020	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)	A Phase IIIB Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Antihistamine;Drug: Methylprednisolone	Hoffmann-La Roche	NULL	Recruiting	18 Years	55 Years	All	699	Phase 3	United States;Argentina;Belgium;Brazil;Bulgaria;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Mexico;Peru;Poland;Portugal;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom
5	NCT04544436 (ClinicalTrials.gov)	November 26, 2020	4/9/2020	A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)	A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis	Multiple Sclerosis	Drug: Ocrelizumab;Drug: Antihistamine;Drug: Methylprednisolone	Hoffmann-La Roche	NULL	Recruiting	18 Years	55 Years	All	865	Phase 3	United States;Argentina;Australia;Belgium;Brazil;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom
6	NCT04601142 (ClinicalTrials.gov)	October 31, 2020	15/10/2020	Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica (NMO) and Gene Polymorphism	Study on the Association Between the Effect of Glucocorticoid Pulse Therapy on Neuromyelitis Optica and Gene Polymorphism: a Cohort Study	Glucocorticoid Resistance;Gene;Neuromyelitis Optica	Drug: Methylprednisolone	Beijing Tongren Hospital	NULL	Recruiting	16 Years	80 Years	All	350		China
7	EUCTR2018-000620-34-DE (EUCTR)	06/05/2020	08/11/2019	Imatinib treatment for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study - Imatinib MS	Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where there are radiological and/or cerebrospinal fluid signs consistent with MS), which display an acute relapse MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 21.0;Level: LLT;Classification code 10028247;Term: Multiple sclerosis like syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	INN or Proposed INN: IMATINIB MESILATE INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Department of Clinical Neuroscience, Karolinska Institutet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 2	Germany;Sweden
8	NCT03829566 (ClinicalTrials.gov)	November 2019	1/2/2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 2/Phase 3	United States
9	NCT02769689 (ClinicalTrials.gov)	June 12, 2019	17/3/2016	Methylprednisolone During the Switch Between Natalizumab and Fingolimod	Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY)	Multiple Sclerosis	Drug: Methylprednisolone;Drug: Placebo;Drug: natalizumab (NTZ);Drug: fingolimob (FTY)	University Hospital, Clermont-Ferrand	NULL	Recruiting	18 Years	65 Years	All	56	Phase 4	France
10	NCT03674099 (ClinicalTrials.gov)	October 1, 2018	14/9/2018	Imatinib for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study	Multiple Sclerosis	Drug: Imatinib Mesylate;Drug: Methylprednisolone	Tomas Olsson	The Swedish Research Council	Recruiting	18 Years	55 Years	All	200	Phase 2	Denmark;Germany;Norway;Sweden
11	EUCTR2017-000635-13-DE (EUCTR)	08/06/2018	22/02/2018	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption	Multiple Sclerosis (MS), acute episode MedDRA version: 20.0;Level: HLT;Classification code 10052785;Term: Multiple sclerosis acute and progressive;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE	Universität Leipzig	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	140	Phase 3	Germany
12	EUCTR2018-000620-34-SE (EUCTR)	24/04/2018	14/03/2018	Imatinib treatment for Multiple Sclerosis (MS) Relapses	Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study - Imatinib MS	Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where there are radiological and/or cerebrospinal fluid signs consistent with MS), which display an acute relapse MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 20.0;Level: LLT;Classification code 10028247;Term: Multiple sclerosis like syndrome;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	INN or Proposed INN: IMATINIB MESILATE Trade Name: Solu-Medrol Product Name: Solu-Medrol INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Department of Clinical Neuroscience, Karolinska Institutet	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Phase 2	Sweden
13	NCT03387046 (ClinicalTrials.gov)	March 26, 2018	22/12/2017	A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)	Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)	Multiple Sclerosis, Relapsing-Remitting	Dietary Supplement: D-aspartate;Drug: Placebo;Biological: IFN beta-1a;Drug: Methylprednisolone	Merck KGaA, Darmstadt, Germany	NULL	Terminated	18 Years	55 Years	All	7	Phase 2	Italy;Germany
14	NCT03342638 (ClinicalTrials.gov)	November 8, 2017	9/11/2017	Maximizing Outcome of Multiple Sclerosis Transplantation	Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial	Multiple Sclerosis, Relapsing-Remitting	Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University	NULL	Terminated	18 Years	58 Years	All	66	Phase 3	United States
15	NCT03368664 (ClinicalTrials.gov)	October 24, 2017	2/11/2017	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)	Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: Glatiramer acetate;Drug: Beta-Interferon;Drug: Methylprednisolone;Drug: Ranitidine;Drug: Ceterizine;Drug: Dexchlorpheniramine;Drug: Paracetamol;Drug: Acyclovir;Drug: Prednisolone;Drug: Diphenydramine;Drug: Other H1 antagonist	Genzyme, a Sanofi Company	NULL	Active, not recruiting	10 Years	17 Years	All	50	Phase 3	Austria;Belgium;France;Italy;Netherlands;Poland;Portugal;Russian Federation;Turkey;United Kingdom;Bulgaria;Czechia;Germany;Greece;Norway;Spain;Switzerland
16	NCT02784210 (ClinicalTrials.gov)	October 5, 2016	26/5/2016	Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques	The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study	Multiple Sclerosis	Drug: Methylprednisolone;Drug: Prednisone	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Recruiting	18 Years	N/A	All	30	Phase 2	United States
17	NCT02583594 (ClinicalTrials.gov)	December 6, 2015	16/10/2015	A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis	A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: Acyclovir;Drug: Methylprednisolone;Drug: alemtuzumab GZ402673;Drug: Paracetamol;Drug: Loratadine;Drug: Ceterizine;Drug: Dexchlorpheniramine	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	All	24	Phase 1	Spain
18	NCT02545959 (ClinicalTrials.gov)	November 30, 2015	7/9/2015	Intrathecal Rituximab in Progressive Multiple Sclerosis	Intrathecal Rituximab in Progressive Multiple Sclerosis	Multiple Sclerosis, Chronic Progressive;Nervous System Diseases	Drug: Rituximab IT;Drug: methylprednisolone IV;Drug: Rituximab IV	Centre Hospitalier de PAU	University Hospital, Bordeaux	Completed	45 Years	N/A	All	10	Phase 2	France
19	EUCTR2014-005493-11-FR (EUCTR)	31/08/2015	15/03/2018	Study the action of a single dose of intrathecally-infused rituximab upon cerebro-spinal fluid (CSF) biological targets, assuming that a definitive action upon CSF biological targets would be strongly predictive of a delayed clinical action in patients with Progressive Multiple Sclerosis.	Intrathecal Rituximab in Progressive Multiple Sclerosis - EFFRITE	Patients included in our study suffer from a progressive form of Multiple sclerosis and will be treated by intravenous and intrathecal rituximab, with intravenous methylprednisolone.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Méthylprednisolone Mylan Product Name: méthylprednisolone Trade Name: Mabthera Product Name: rituximab Trade Name: Mabthera Product Name: rituximab	Centre Hospitalier de Pau	NULL	Not Recruiting			Female: yes Male: yes	12	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	France
20	NCT02398994 (ClinicalTrials.gov)	March 2015	23/3/2015	A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis	A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children	Myelitis, Transverse;Neuromyelitis Optica	Drug: Intravenous Methylprednisolone;Drug: Intravenous Immunoglobulin	Guy's and St Thomas' NHS Foundation Trust	King's College London;Barts and the London School of Medicine and Dentistry;Cardiff University;University College, London;King's College Hospital NHS Trust;Great Ormond Street Hospital for Children NHS Foundation Trust;Barts & The London NHS Trust;Alder Hey Children's NHS Foundation Trust;Walton Centre NHS Foundation Trust;Oxford University Hospitals NHS Trust;Birmingham Children's Hospital NHS Foundation Trust;University Hospital Birmingham NHS Foundation Trust;Cardiff and Vale University Health Board;North Bristol NHS Trust;University Hospitals Bristol NHS Foundation Trust;Central Manchester University Hospitals NHS Foundation Trust;Salford Royal NHS Foundation Trust;University Hospital Southampton NHS Foundation Trust.;Newcastle-upon-Tyne Hospitals NHS Trust;Nottingham University Hospitals NHS Trust;NHS Lothian	Terminated	1 Year	N/A	Both	2	Phase 3	United Kingdom
21	NCT02205489 (ClinicalTrials.gov)	October 2014	29/7/2014	Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA	Relapsing-remitting Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: cetirizine;Drug: ranitidine;Drug: methylprednisolone;Drug: aciclovir;Drug: esomeprazole;Drug: ibuprofen;Drug: paracetamol	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	Both	58	Phase 4	Belgium;France;Netherlands;Spain
22	NCT02087813 (ClinicalTrials.gov)	March 2014	11/3/2014	Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses	A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks	Neuromyelitis Optica	Drug: Alpha1-antitrypsin;Drug: methylprednisolone	Stanford University	NULL	Withdrawn	18 Years	75 Years	All	0	Phase 1	United States
23	NCT02048358 (ClinicalTrials.gov)	November 2013	17/1/2014	Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients	Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201	Healthy Volunteers;Multiple Sclerosis	Drug: 2B3-201;Drug: Placebo;Drug: Methylprednisolone hemisuccinate	BBB-Therapeutics B.V.	NULL	Terminated	18 Years	65 Years	Both	47	Phase 1	Netherlands
24	NCT01986998 (ClinicalTrials.gov)	October 2013	11/1/2013	Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse	Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse.	Multiple Sclerosis	Drug: Methylprednisolone 1250 mg/24h x3 days;Drug: Oral Methylprednisolone 625 mg/24h x3 days	Germans Trias i Pujol Hospital	NULL	Completed	18 Years	59 Years	Both	49	Phase 4	Spain
25	EUCTR2012-004807-10-DE (EUCTR)	17/07/2013	26/10/2012	Relapse Escalation treatment trial in Optic Neuritis (RESCON):Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis	Relapse Escalation treatment trial in Optic Neuritis (RESCON):Multi-centre RCT to study the efficacy of plasma exchange (PE) as an escalation treatment strategy in steroid-unresponsive Optic Neuritis	MS patients who suffer from severe Optic Neuritis without satisfying improvement after treatment with steroids (3-5 days with 1 g daily at least 7 days prior to randomization) and with persisting visual acuity < 0.7, duration of symptoms should be = 4 weeks MedDRA version: 14.1;Level: PT;Classification code 10063400;Term: Secondary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders MedDRA version: 14.1;Level: LLT;Classification code 10070425;Term: Multiple sclerosis exacerbation;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;Classification code 10048393;Term: Multiple sclerosis relapse;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Urbason® solubile forte 1000 mg Product Name: Methylprednisolone INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE	University Medical Center Hamburg Eppendorf	NULL	Not Recruiting			Female: yes Male: yes	40	Phase 2	Germany
26	NCT01710228 (ClinicalTrials.gov)	July 2013	4/9/2012	Alternative Treatment Paradigm for Natalizumab Trial	Alternative Treatment Paradigm for Natalizumab Trial	Multiple Sclerosis (MS)	Drug: methylprednisolone	University of Texas Southwestern Medical Center	Teva Pharmaceutical Industries;The University of Texas Health Science Center, Houston;University of Alabama at Birmingham;Charite University, Berlin, Germany	Withdrawn	18 Years	60 Years	Both	0	Phase 2	United States
27	NCT01900093 (ClinicalTrials.gov)	July 2013	11/7/2013	Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses	An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone	Multiple Sclerosis	Drug: Acthar Gel	Aaron Miller	Mallinckrodt	Recruiting	18 Years	65 Years	All	10	N/A	United States
28	NCT01838174 (ClinicalTrials.gov)	May 2013	18/4/2013	A Trial of Neuroprotection With ACTH in Acute Optic Neuritis	A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis	Multiple Sclerosis	Drug: ACTHAR Gel (ACTH);Drug: IV methylprednisolone (steroids)	University of Colorado, Denver	Mallinckrodt;University of Pennsylvania	Terminated	18 Years	55 Years	All	100	Phase 4	United States
29	EUCTR2012-001965-34-ES (EUCTR)	07/11/2012	09/08/2012	Study to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.	Multicenter, randomized, double-blind clinical trial to compare the clinical and radiological efficacy of 625 mg vs 1250 mg of oral methylprednisolone in patients with multiple sclerosis in relapse.	Multiple sclerosis MedDRA version: 15.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Urbason 40 mg Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE	Servicio de Neurología, HU. Germans Trias i Pujol	NULL	Not Recruiting			Female: yes Male: yes		Phase 4	Spain
30	EUCTR2010-024561-43-DK (EUCTR)	24/05/2011	07/02/2011	Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis	Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis	progressive multiple sclerosis MedDRA version: 13.1;Level: PT;Classification code 10053395;Term: Progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders	Trade Name: Medrol Other descriptive name: METHYLPREDNISOLONE	Scleroseklinikken, Rigshospitalet	NULL	Not Recruiting			Female: yes Male: yes	30		Denmark
31	NCT01305837 (ClinicalTrials.gov)	April 2011	28/2/2011	Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis	Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis	Progressive Multiple Sclerosis	Drug: methylprednisolone	Rigshospitalet, Denmark	NULL	Completed	18 Years	65 Years	Both	30	Phase 2	Denmark
32	EUCTR2009-013884-21-PL (EUCTR)	20/05/2010	13/01/2010	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome MedDRA version: 14.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PEG-liposomal Prednisolone Sodium Phosphate Product Code: Nanocort INN or Proposed INN: Prednisolone Sodium Phosphate Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE Trade Name: Solu-Medrol INN or Proposed INN: METHYLPREDNISOLONE SODIUM SUCCINATE Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Enceladus Pharmaceuticals BV	NULL	Not Recruiting			Female: yes Male: yes	90		Germany;Belgium;Poland
33	EUCTR2009-017490-38-DE (EUCTR)	03/05/2010	01/02/2010	Randomized Treatment Interruption of Natalizumab - RESTORE	Randomized Treatment Interruption of Natalizumab - RESTORE	Natalizumab is a highly efficacious therapy used in the treatment of patients with relapsing multiple sclerosis (MS).This is a prospective randomized study in subjects with relapsing forms of MS who have been receiving natalizumab treatment for at least 12 months with no MS relapses during these 12 months. MedDRA version: 12.1;Level: LLT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis	Trade Name: Tysabri INN or Proposed INN: NATALIZUMAB Other descriptive name: TYSABRI Trade Name: Copaxone INN or Proposed INN: GLATIRAMER ACETATE Other descriptive name: COPAXONE Trade Name: AVONEX INN or Proposed INN: INTERFERON BETA-1A Other descriptive name: AVONEX Trade Name: Urbason Forte INN or Proposed INN: METHYLPREDNISOLONE Other descriptive name: URBASON FORTE	Biogen Idec	NULL	Not Recruiting			Female: yes Male: yes	200		Germany;Spain
34	NCT01071083 (ClinicalTrials.gov)	March 2010	17/2/2010	Treatment Interruption of Natalizumab	Randomized Treatment Interruption of Natalizumab	Relapsing Remitting Multiple Sclerosis	Drug: natalizumab;Drug: interferon beta 1-a;Drug: methylprednisolone;Other: IV placebo;Drug: glatiramer acetate	Biogen	Elan Pharmaceuticals	Completed	18 Years	60 Years	All	175	Phase 2	United States;Germany;Spain
35	NCT01039103 (ClinicalTrials.gov)	December 2009	20/12/2009	Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)	A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort®) vs Intravenous Methylprednisolone (Solu-Medrol®) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS)	Acute Exacerbation of Remitting Relapsing Multiple Sclerosis;Clinically Isolated Syndrome	Drug: PEG-liposomal prednisolone sodium phosphate;Drug: Methylprednisolone	Galapagos NV	NULL	Terminated	18 Years	65 Years	Both	15	Phase 2	Belgium;Germany;Poland
36	EUCTR2009-013884-21-DE (EUCTR)	18/11/2009	09/09/2009	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome MedDRA version: 14.0;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PEG-liposomal Prednisolone Sodium Phosphate Product Code: Nanocort INN or Proposed INN: Prednisolone Sodium Phosphate Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE Trade Name: Solu-Medrol INN or Proposed INN: METHYLPREDNISOLONE SODIUM SUCCINATE Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Enceladus Pharmaceuticals BV	NULL	Not Recruiting			Female: yes Male: yes	90		Poland;Belgium;Germany
37	EUCTR2009-013884-21-BE (EUCTR)	13/11/2009	10/09/2009	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	A randomized, international, multi centre study to assess the efficacy and safety of intravenous PEG-liposomal prednisolone sodium phosphate (Nanocort®) vs intravenous methylprednisolone (Solu-Medrol®) treatment in patients with acute exacerbation of relapsing-remitting Multiple Sclerosis or in patients with clinically isolated syndrome (CIS)	Patients with acute exacerbation of Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome MedDRA version: 20.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: PEG-liposomal Prednisolone Sodium Phosphate Product Code: Nanocort INN or Proposed INN: Prednisolone Sodium Phosphate Other descriptive name: PREDNISOLONE SODIUM PHOSPHATE Trade Name: Solu-Medrol INN or Proposed INN: METHYLPREDNISOLONE SODIUM SUCCINATE Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Enceladus Pharmaceuticals BV	NULL	Not Recruiting			Female: yes Male: yes	90	Phase 2	Poland;Belgium;Germany
38	NCT01049451 (ClinicalTrials.gov)	November 2009	13/1/2010	Pulse ACTH vs. MP for MS	Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)	Multiple Sclerosis	Drug: ACTH;Drug: Methylprednisolone	University of Southern California	NULL	Completed	18 Years	65 Years	All	23	Phase 1	United States
39	NCT00947895 (ClinicalTrials.gov)	October 2009	2/7/2009	Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone	Relative Efficacy of Repeat Course of Intravenous methyLprednisolone and Intramuscular ACTH in the Treatment of Acute Relapse of Multiple Sclerosis After Sub Response to Initial Course of Intravenous Methylprednisolone (RECLAIM): a Single Center Pilot Study	Multiple Sclerosis	Drug: Methylprednisolone;Drug: ACTH;Other: IV placebo;Other: IM placebo	Neurologique Foundation, Inc.	Mallinckrodt	Terminated	18 Years	N/A	Both	30	Phase 2/Phase 3	United States
40	EUCTR2009-011516-37-DK (EUCTR)	29/05/2009	15/05/2009	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS	Double blind, placebo-controlled study to assess the effects of Erythropoietin on clinical disability and brain pathology as shown by magnetic resonance imaging in patients with progressive multiple sclerosis - EPO-ProgMS	Multiple Sclerosis, with primary and secondary progressive courses. MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: NeoRecormon INN or Proposed INN: Solu-Medrol Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Danish Multiple Sclerosis Research Centre	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	Denmark
41	NCT00764413 (ClinicalTrials.gov)	April 2009	1/10/2008	Chronotherapy in Acute Multiple Sclerosis (MS) Attack	Treatment With Methylprednisolone in Acute Exacerbations of Multiple Sclerosis: Enhanced Effect With Nighttime Treatment?	Multiple Sclerosis	Drug: methylprednisolone;Drug: Sodium chlorid	Sykehuset Innlandet HF	NULL	Terminated	18 Years	N/A	Both	57	N/A	Norway
42	EUCTR2008-005304-93-GB (EUCTR)	13/02/2009	12/12/2008	A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis	A Randomised Control Trial To Evaluate Whether Zoledronate Prevents Bone Loss In Acute Exacerbations Of Multiple Sclerosis - Zoledronate in multiple sclerosis	Bone loss in patients with Multiple Sclerosis (MS) who require large short term doses of methylprednisolone for exacerbations of their disease. MedDRA version: 9.1;Level: LLT;Classification code 10048393;Term: Multiple sclerosis relapse MedDRA version: 9.1;Classification code 10065687;Term: Bone loss	Trade Name: Aclasta 5mg solution for infusion Product Name: Aclasta Product Code: ZOL446H	North Bristol Trust	NULL	Not Recruiting			Female: yes Male: yes			United Kingdom
43	NCT00753792 (ClinicalTrials.gov)	November 2008	16/9/2008	Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse	Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse	Multiple Sclerosis	Drug: methylprednisolone;Drug: Placebo	Germans Trias i Pujol Hospital	NULL	Completed	18 Years	59 Years	Both	49	Phase 4	Spain
44	EUCTR2007-000888-15-ES (EUCTR)	19/05/2008	27/02/2008	ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO,PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DEMETILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRAVENOSA ENPACIENTES EN BROTE DE ESCLEROSIS MÚLTIPLE - Corticoterapia Oral en Megadosis para el Tratamiento del Brote de Esclerosis Múltiple	ENSAYO CLÍNICO, MULTICÉNTRICO, CON ASIGNACIÓN ALEATORIA Y DOBLE CIEGO,PARA COMPARAR LA EFICACIA CLÍNICA Y RADIOLÓGICA DE DOSIS EQUIVALENTES DEMETILPREDNISOLONA ADMINISTRADAS POR VÍA ORAL O VÍA INTRAVENOSA ENPACIENTES EN BROTE DE ESCLEROSIS MÚLTIPLE - Corticoterapia Oral en Megadosis para el Tratamiento del Brote de Esclerosis Múltiple	Pacientes afectos de esclerosis múltiple MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: SOLU-MODERIN 1 g INN or Proposed INN: METHYLPREDNISOLONE Trade Name: URBASON 40 mg comprimidos INN or Proposed INN: METHYLPREDNISOLONE	Servicio de Neurología	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Spain
45	EUCTR2007-002179-15-FR (EUCTR)	04/03/2008	22/11/2007	Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques - CORTICOFLASH	Etude des effets de la méthylprednisolone à fortes doses sur les caractéritiques électrophysiologiques de la fatigabilité à l'effort au cours des poussées de sclérose en plaques - CORTICOFLASH	Méthylprednisolone administrée aux patients et contrôles à la dose de 1g/j pendant 3 jours, comme prescrit habituellement dans le cadre de leur pathologie. MedDRA version: 8.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis	Trade Name: Methylprednisolone Product Name: Methylprednisolone INN or Proposed INN: Methylprednisolone	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
46	NCT00984984 (ClinicalTrials.gov)	March 2008	24/9/2009	Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses	Randomised Double-blinded Trial Comparing Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis Relapses	Multiple Sclerosis, Relapsing-Remitting	Drug: methylprednisolone PO;Drug: methylprednisolone IV	Rennes University Hospital	NULL	Recruiting	18 Years	55 Years	Both	200	Phase 3	France
47	EUCTR2007-000590-37-FR (EUCTR)	17/07/2007	23/05/2007	Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques - COPOUSEP	Etude randomisée, en double aveugle, comparant l’efficacité et la tolérance de la méthylprednisolone administrée à forte dose par voie orale ou par voie intraveineuse dans le traitement des poussées de sclérose en plaques - COPOUSEP	Traitement des poussées de sclérose en plaques MedDRA version: 9.1;Level: LLT;Classification code 10028245;Term: Multiple sclerosis	Product Name: METHYLPREDNISOLONE INN or Proposed INN: METHYLPREDNISOLONE Trade Name: methylprednisolone Product Name: methylprednisolone Trade Name: methylprednisolone Product Name: methylprednisolone	CHU Rennes	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			France
48	EUCTR2005-005592-14-DE (EUCTR)	27/07/2006	12/05/2006	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect	Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect	Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is mainly characterized by a subacute loss of vision.	Trade Name: Erypo/Erypo FS Product Name: Erypo/Erypo FS INN or Proposed INN: Epoetin alfa Other descriptive name: Epo Trade Name: Urbason solubile forte 1000mg Product Name: Methylprednisolone INN or Proposed INN: Methylprednisolon-21-hydrogensuccinat, Natriumsalz	IFSgGmbH, Institute for clinical research	NULL	Not Recruiting			Female: yes Male: yes			Germany
49	NCT00241254 (ClinicalTrials.gov)	December 2005	17/10/2005	Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis	A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study	Multiple Sclerosis, Chronic Progressive	Drug: Cyclophosphamide (drug);Drug: Methylprednisolone (drug)	University Hospital, Bordeaux	Ministry of Health, France	Completed	18 Years	65 Years	Both	138	Phase 3	France
50	NCT00493116 (ClinicalTrials.gov)	October 2003	25/6/2007	Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta	A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon-beta-1a;Drug: methylprednisolone	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	20	Phase 4	Australia;New Zealand
51	NCT00418145 (ClinicalTrials.gov)	September 2003	2/1/2007	Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks	Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)	Multiple Sclerosis	Drug: megadose oral methylprednisolone;Drug: IV methylprednisolone	Fred Lublin	National Multiple Sclerosis Society;Pfizer	Terminated	18 Years	50 Years	All	16	Phase 3	United States
52	NCT00112034 (ClinicalTrials.gov)	June 2003	27/5/2005	AVONEX® Combination Trial - ACT	A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX Compared With AVONEX in Combination With Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects With Relapsing Remitting MS Who Have Breakthrough Disease on AVONEX Monotherapy.	Multiple Sclerosis, Relapsing-Remitting	Drug: Methotrexate;Drug: IV methylprednisolone	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	350	Phase 4	United States
53	NCT00492466 (ClinicalTrials.gov)	March 2003	25/6/2007	Investigating if Interferon-Beta Can be Used in Patients With MS After They Have Developed Neutralizing Antibodies	A Multicentre, Open Label, Non-Comparative Trial Investigating the Recovering of INF-Beta Efficacy in Breakthrough Relapsing-Remitting Multiple Sclerosis Patients With Neutralizing Interferon-Beta Antibodies	Relapsing-Remitting Multiple Sclerosis	Drug: Interferon-beta-1a;Drug: methylprednisolone	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	14	Phase 4	Finland
54	NCT00168766 (ClinicalTrials.gov)	January 2003	13/9/2005	Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS	A Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Investigating Methylprednisolone in Combination With Interferon-beta-1a for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis	Relapsing-remitting Multiple Sclerosis	Drug: Interferon-beta-1a (Avonex) plus methylprednisolone	Biogen Idec	NULL	Completed	18 Years	55 Years	Both	345	Phase 4	Belgium;Denmark;Finland;Netherlands;Norway;Sweden;Switzerland;United Kingdom
55	NCT00037115 (ClinicalTrials.gov)	May 2002	15/5/2002	Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.	An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results.	Demyelinating Disorders;Multiple Sclerosis;Optic Neuritis;Myelitis;Neuritis	Drug: interferon beta 1a;Drug: methotrexate;Drug: methylprednisolone	MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute	Consultants in Neurology	Withdrawn	18 Years	50 Years	All	0	Phase 4	United States
56	NCT00017628 (ClinicalTrials.gov)	April 2001	6/6/2001	Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis		Multiple Sclerosis	Drug: cyclophosphamide;Drug: filgrastim;Drug: methylprednisolone;Procedure: Autologous Stem Cell Transplantation	Northwestern Memorial Hospital	NULL	Completed	N/A	59 Years	Both	20	Phase 1	United States
57	NCT00000146 (ClinicalTrials.gov)	July 1988	23/9/1999	Optic Neuritis Treatment Trial (ONTT)		Multiple Sclerosis;Optic Neuritis	Drug: Methylprednisolone;Drug: Prednisone	National Eye Institute (NEI)	NULL	Active, not recruiting	18 Years	46 Years	Both		Phase 3	United States
58	NCT00000147 (ClinicalTrials.gov)	July 1988	23/9/1999	Longitudinal Optic Neuritis Study (LONS)		Multiple Sclerosis;Optic Neuritis	Drug: Methylprednisolone;Drug: Prednisone	National Eye Institute (NEI)	NULL	Active, not recruiting	18 Years	46 Years	Both		N/A	United States

先頭へ

14. 慢性炎症性脱髄性多発神経炎／多巣性運動ニューロパチー

臨床試験数 : 175 / 薬物数 : 161 - (DrugBank : 41) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-002511-34-GB (EUCTR)	01/04/2019	08/11/2019	Initial treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) - combined immunoglobulin and steroid treatment versus immunoglobulin treatment alone.	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP - OPTIC Trial	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) MedDRA version: 21.1;Level: PT;Classification code 10057645;Term: Chronic inflammatory demyelinating polyradiculoneuropathy;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: methylprednisolone Product Name: methylprednisolone Trade Name: sodium chloride 0.9% Product Name: sodium chloride 0.9%	Academic Medical Centre, Amsterdam, NL	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	96	Phase 3	Netherlands;United Kingdom
2	EUCTR2017-002511-34-NL (EUCTR)	26/09/2018	17/04/2018	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP(OPTIC trial)	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP(OPTIC trial) - OPTIC trial	Chronic inflammatory demyelinating polyneuropathy (CIDP);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Methylprednisolone (Solu-Medrol) Product Name: Methylprednisolon (Solu-Medrol) Trade Name: Sodium Chloride 0.9% Product Name: Sodium Chloride 0.9% Product Code: RVG 56083	Academisch Medisch Centrum	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	96	Phase 3	Netherlands

18. 脊髄小脳変性症（多系統萎縮症を除く。）

臨床試験数 : 76 / 薬物数 : 98 - (DrugBank : 31) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02424435 (ClinicalTrials.gov)	June 2015	16/4/2015	Methylprednisolone Treatment of Friedreich Ataxia	Open-label Pilot Study of Methylprednisolone for the Treatment of Patients With Friedreich Ataxia (FRDA)	Friedreich Ataxia	Drug: Methylprednisolone	Children's Hospital of Philadelphia	Friedreich's Ataxia Research Alliance	Completed	5 Years	N/A	All	11	Early Phase 1	United States

19. ライソゾーム病

臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05487599 (ClinicalTrials.gov)	December 20, 2022	1/6/2022	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	Gaucher Disease	Biological: LY3884961;Drug: Methylprednisolone;Drug: Sirolimus;Drug: Prednisone	Prevail Therapeutics	Eli Lilly and Company	Recruiting	18 Years	50 Years	All	15	Phase 1/Phase 2	United States
2	NCT03952637 (ClinicalTrials.gov)	August 19, 2019	15/5/2019	A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	Lysosomal Diseases;Gangliosidosis;GM1	Biological: AAV9-GLB1;Procedure: Abdominal ultrasound;Drug: Rituximab;Drug: Sirolimus;Drug: Methylprednisolone;Drug: Prednisone;Diagnostic Test: Audiology assessment with ABR;Diagnostic Test: Bone density scan (DEXA);Diagnostic Test: Electrocardiogram (EKG);Diagnostic Test: Echocardiogram;Other: Electroencephalogram (EEG) awake and extended overnight;Diagnostic Test: Laboratory tests;Procedure: Lumbar puncture;Procedure: Brain MRI/MRS/fMRI;Behavioral: Neurocognitive testing;Other: Neurology exam;Behavioral: PICC or other Central line placement;Procedure: Skeletal survey;Procedure: Skin biopsy;Procedure: Speech and modified barium swallow study;Procedure: Ophthalmology exam	National Human Genome Research Institute (NHGRI)	Sio Gene Therapies	Active, not recruiting	6 Months	12 Years	All	16	Phase 1/Phase 2	United States

25. 進行性多巣性白質脳症

臨床試験数 : 26 / 薬物数 : 35 - (DrugBank : 22) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 37

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-020369-26-DE (EUCTR)	29/11/2010	18/08/2010	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab	Immune Reconstitution Inflammatory Syndrome MedDRA version: 12.1;Level: PT;Classification code 10054014;Term: Immune reconstitution syndrome	Product Name: methylprednisolone INN or Proposed INN: METHYLPREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE	Biogen Idec	NULL	Not Recruiting			Female: yes Male: yes	20		Germany
2	NCT01211665 (ClinicalTrials.gov)	September 2010	29/7/2010	Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)	High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab	Immune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive Multifocal	Drug: Methylprednisolone;Drug: Prednisolone	Biogen	Elan Pharmaceuticals	Terminated	18 Years	N/A	All	3	Phase 4	United States;Germany

26. HTLV-1関連脊髄症

臨床試験数 : 29 / 薬物数 : 47 - (DrugBank : 29) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 119

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000024086	2016/09/16	20/09/2016	Phase IIb clinical trial of steroid therapy in patients with HAM(Non progressor)	Phase IIb clinical trial of steroid therapy in patients with HAM(Non progressor) - HAMLET-P	HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)	Drugs which possibly affect assessment in the study (e.g. methylprednisolone, prednisolone and other agents targeted to HAM) will be forbidden or limited until Week 48 and periodic evaluation and tests will be performed.	St. Marianna University School of Medicine Hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	5	Phase 2	Japan
2	JPRN-UMIN000023798	2016/08/31	31/08/2016	Phase IIb clinical trial of steroid therapy in patients with HAM	Phase IIb clinical trial of steroid therapy in patients with HAM - HAMLET-P	HTLV-1-Associated-Myelopathy Tropical Spastic Paraparesis (HAM/TSP)	Following to administrate Methylprednisolone 1000mg/day intravenously slowly for consecutive three days, Prednisolone is administered orally for a maximum dose in 0.5mg/kg/day, then decreased gradually and terminated. There is a case to maintain the dose of Prednisolone by the degree of a progress of underlying disease. Prednisolone is administered orally for a maximum dose in 0.5mg/kg/day, then decreased gradually and terminated. There is a case to maintain the dose of Prednisolone by the degree of a progress of underlying disease.	St. Marianna University School of Medicine Hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	8	Phase 2,3	Japan

35. 天疱瘡

臨床試験数 : 99 / 薬物数 : 124 - (DrugBank : 36) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1800020382	2019-01-01	2018-12-27	Efficacy and safety of ultra-low dosage regimen of rituximab combined with corticosteroids in the treatment of pemphigus	Efficacy and safety of ultra-low dosage regimen of rituximab combined with corticosteroids in the treatment of pemphigus	Pemphigus	Group 1:Rituximab 500mg single infusion combined with routinedose of corticosteriods therapy;Group 2:Rituximab 100mg single infusion combined with routinedose of corticosteriods therapy;Group 3:Oral or intravenous infusion of routinedose of corticosteriods (prednisone or methylprednisolone);	West China Hospital, Sichuna University	NULL	Recruiting	18	80	Both	Group 1:14;Group 2:14;Group 3:14;		China

38. スティーヴンス・ジョンソン症候群

臨床試験数 : 17 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 101

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs061180044	01/06/2017	12/03/2019	Multicenter Open-trial of Steroid pulse therapy for SJS/TEN	Multicenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study	Stevens-Johnson syndrome and Toxic epidermal necrolysis	1. infusion of methylprednisolone at 500~1000 mg/d (0.9% N/S in 3 hour) for 3 consecutive days. 2. Oral predonisolone (0.5 mg/kg/d) was initiated on the day following the last dose of methylprednisolone, and prednisolone was subsequently tapered within 2 weeks. If the ocular involvement score is more than 2, dose of oral predonisolone (1 mg/kg/d) is recommended.	Morita Eishin	NULL	Complete	>= 20age old	<= 90age old	Both	20	Phase 2	Taiwan;Germany;Japan

39. 中毒性表皮壊死症

臨床試験数 : 13 / 薬物数 : 19 - (DrugBank : 8) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs061180044	01/06/2017	12/03/2019	Multicenter Open-trial of Steroid pulse therapy for SJS/TEN	Multicenter Open-trial of Steroid pulse therapy for SJS/TEN - MOSST Study	Stevens-Johnson syndrome and Toxic epidermal necrolysis	1. infusion of methylprednisolone at 500~1000 mg/d (0.9% N/S in 3 hour) for 3 consecutive days. 2. Oral predonisolone (0.5 mg/kg/d) was initiated on the day following the last dose of methylprednisolone, and prednisolone was subsequently tapered within 2 weeks. If the ocular involvement score is more than 2, dose of oral predonisolone (1 mg/kg/d) is recommended.	Morita Eishin	NULL	Complete	>= 20age old	<= 90age old	Both	20	Phase 2	Taiwan;Germany;Japan

40. 高安動脈炎

臨床試験数 : 24 / 薬物数 : 40 - (DrugBank : 18) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 110

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States

41. 巨細胞性動脈炎

臨床試験数 : 131 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States

42. 結節性多発動脈炎

臨床試験数 : 15 / 薬物数 : 26 - (DrugBank : 16) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 105

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00307671 (ClinicalTrials.gov)	July 2005	27/3/2006	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants	Vasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Polyarteritis Nodosa	Drug: prednisone, methylprednisolone,cyclophosphamides;Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Drug: Mycophenolate mofetil,methotrexate	Assistance Publique - Hôpitaux de Paris	NULL	Completed	65 Years	N/A	Both	108	Phase 4	France
2	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States

43. 顕微鏡的多発血管炎

臨床試験数 : 88 / 薬物数 : 81 - (DrugBank : 21) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00307671 (ClinicalTrials.gov)	July 2005	27/3/2006	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants	Vasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Polyarteritis Nodosa	Drug: prednisone, methylprednisolone,cyclophosphamides;Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Drug: Mycophenolate mofetil,methotrexate	Assistance Publique - Hôpitaux de Paris	NULL	Completed	65 Years	N/A	Both	108	Phase 4	France
2	NCT00104299 (ClinicalTrials.gov)	January 2005	24/2/2005	Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis	Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)	Vasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis	Drug: Rituximab plus cyclophosphamide placebo (rituximab group);Drug: Cyclophosphamide plus rituximab placebo (control group);Drug: Azathioprine;Drug: Methylprednisolone (or other glucocorticoid);Drug: Prednisone	National Institute of Allergy and Infectious Diseases (NIAID)	Immune Tolerance Network (ITN);Genentech, Inc.	Completed	15 Years	N/A	All	197	Phase 2/Phase 3	United States;Netherlands
3	NCT00307645 (ClinicalTrials.gov)	May 2003	27/3/2006	IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis	Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis	ANCA Associated Systemic Vasculitis Including Wegener’s;Granulomatosis and Microscopic Polyangiitis and;Renal Limited Vasculitis	Drug: Cyclophosphamide;Drug: Mycophenolate mofetil;Drug: Azathioprine;Drug: Prednisone (and methylprednisolone)	Assistance Publique - Hôpitaux de Paris	NULL	Terminated	18 Years	N/A	Both	160	Phase 3	France;United Kingdom
4	NCT00753103 (ClinicalTrials.gov)	January 2003	15/9/2008	Anti-Cytokine Therapy for Vasculitis	Phase II Pilot Cohort Study to Investigate the Safety and Efficacy of Infliximab as Additional Therapy in the Treatment if Anti-Neutrophil Cytoplasm Antibody Associated Vasculitis	Wegener's Granulomatosis;Renal Limited Vasculitis;Microscopic Polyangiitis	Biological: Infliximab;Drug: Cyclophosphamide;Drug: Prednisolone;Drug: Azathioprine;Procedure: Plasma exchange;Drug: Mycophenolate mofetil;Drug: Methylprednisolone	University Hospital Birmingham NHS Foundation Trust	NULL	Completed	18 Years	N/A	Both	37	Phase 2	United Kingdom

45. 好酸球性多発血管炎性肉芽腫症

臨床試験数 : 31 / 薬物数 : 44 - (DrugBank : 18) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 101

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00307671 (ClinicalTrials.gov)	July 2005	27/3/2006	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years	Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants	Vasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Polyarteritis Nodosa	Drug: prednisone, methylprednisolone,cyclophosphamides;Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Drug: Mycophenolate mofetil,methotrexate	Assistance Publique - Hôpitaux de Paris	NULL	Completed	65 Years	N/A	Both	108	Phase 4	France
2	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000033059	2018/06/20	20/06/2018	The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial	The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial - The impact of including corticosteroid in a periarticular injection for pain control after total hip arthroplasty: a double blind randomized controlled trial	Osteoarthritis of the hip, rheumatoid arthritis, avascular necrosis of the femoral head, femoral neck fracture	A periarticular injection including methylprednisolone, ropivacaine, morphine, bosmin, and ketoprofen for pain after total hip arthroplasty A periarticular injection including ropivacaine, morphine, bosmin, and ketoprofen for pain after total hip arthroplasty	Hokusuikai Kinen Hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	120	Not selected	Japan
2	JPRN-UMIN000029759	2017/11/01	01/11/2017	Percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty as a component of multimodal pain management: a randomized control trial	Percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty as a component of multimodal pain management: a randomized control trial - Percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty as a component of multimodal pain management: a randomized control trial	Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	Percutaneous periarticular analgesic injection including methylprednisolone 80 mg [2 mL], ropivacaine 150 mg [20 mL], and epinephrine 0.2 mg [0.2 mL] at one day after simultaneous bilateral total knee arthroplasty No percutaneous periarticular analgesic injection at one day after simultaneous bilateral total knee arthroplasty	Nekoyama Miyao Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	32	Not selected	Japan
3	JPRN-UMIN000029003	2017/10/01	05/09/2017	Percutaneous periarticular analgesic injection at one day after total knee arthroplasty as a component of multimodal pain management: a randomized control trial	Percutaneous periarticular analgesic injection at one day after total knee arthroplasty as a component of multimodal pain management: a randomized control trial - Percutaneous periarticular analgesic injection at one day after total knee arthroplasty as a component of multimodal pain management: a randomized control trial	Osteoarthritis, Avascular necrosis of femoral condyle, Rheumatoid arthritis	Percutaneous periarticular analgesic injection including methylprednisolone 40 mg [1 mL], ropivacaine 150 mg [20 mL], and epinephrine 0.1 mg [0.1 mL] at one day after total knee arthroplasty No percutaneous periarticular analgesic injection at one day after total knee arthroplasty	Nekoyama Miyao Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	40	Not selected	Japan
4	EUCTR2015-002924-17-BE (EUCTR)	24/02/2016	27/01/2016	A Study To Evaluate The Efficacy And Safety Of Intravenous Nanocort Compared With A Intramuscular Injection of Methylprednisolone Acetate In Patients With Rheumatoid Arthritis	A Phase III, Randomized, Double-Blind, Double Dummy, Active Controlled, Multi-Center Study To Evaluate The Efficacy And Safety Of Intravenous Pegylated Liposomal Prednisolone Sodium Phosphate (Nanocort) Compared With Intramuscular Injection Of Methylprednisolone Acetate In Subjects With Active Rheumatoid Arthritis	Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Nanocort INN or Proposed INN: prednisolone Other descriptive name: PREDNISOLONE Trade Name: Depo Medrol Product Name: Depo Medrol	Sun Pharma Global FZE	NULL	Not Recruiting			Female: yes Male: yes	330	Phase 3	Belgium;Netherlands
5	EUCTR2015-002924-17-NL (EUCTR)	12/11/2015	06/10/2015	A Study To Evaluate The Efficacy And Safety Of Intravenous Nanocort Compared With A Intramuscular Injection of Methylprednisolone Acetate In Patients With Rheumatoid Arthritis	A Phase III, Randomized, Double-Blind, Double Dummy, Active Controlled, Multi-Center Study To Evaluate The Efficacy And Safety Of Intravenous Pegylated Liposomal Prednisolone Sodium Phosphate (Nanocort) Compared With Intramuscular Injection Of Methylprednisolone Acetate In Subjects With Active Rheumatoid Arthritis	Active Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Nanocort INN or Proposed INN: prednisolone Other descriptive name: PREDNISOLONE Trade Name: Depo Medrol Product Name: Depo Medrol	Sun Pharma Global FZE	NULL	Not Recruiting			Female: yes Male: yes	330	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	Belgium;Netherlands
6	EUCTR2014-004472-35-NL (EUCTR)	02/03/2015	01/12/2014	TREAT EARLY ARTHRALGIA TO REVERSE OR LIMIT IMPENDING EXACERBATION TO RHEUMATOID ARTHRITIS	TREAT EARLY ARTHRALGIA TO REVERSE OR LIMIT IMPENDING EXACERBATION TO RHEUMATOID ARTHRITIS	Arthralgia of hands or feet of patients that are suspect to progress to reumatoid arthritis according to the treating rheumatologist and because of subclinical inflammation on MRI of hands and feet (Clinical Suspect Artralgia CSA);Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Methotrexaat Product Name: Methotrexaat Product Code: L04AX03 INN or Proposed INN: Methotrexate Other descriptive name: METHOTREXATE Trade Name: Methylprednisolone Product Name: Methylprednisolone Product Code: H02AB04 INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE ACETATE	Leiden University medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	230	Phase 2	Netherlands
7	JPRN-UMIN000012257	2013/11/12	11/11/2013	Impact of corticosteroid on periarticular injection for pain control following total knee arthroplasty: a double-blind randomized trial	Impact of corticosteroid on periarticular injection for pain control following total knee arthroplasty: a double-blind randomized trial - Impact of corticosteroid on periarticular injection for pain control following total knee arthroplasty: a double-blind randomized trial	osteoarthritis, rheumatoid arthritis, avascular necrosis of femoral condyle	A periarticular injection including methylprednisolone, ropivacaine, morphine, bosmin, and ketoprofen for pain after total knee arthroplasty A periarticular injection including ropivacaine, morphine, bosmin, and ketoprofen for pain after total knee arthroplasty	Nekoyama Miyao Hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	74	Not selected	Japan
8	JPRN-UMIN000011181	2012/11/19	12/07/2013	Continuous epidural infusion versus periarticular multimodal drug injection in bilateral simultaneous total knee arthroplasty: a randomized controlled trial	Continuous epidural infusion versus periarticular multimodal drug injection in bilateral simultaneous total knee arthroplasty: a randomized controlled trial - Continuous epidural infusion versus periarticular multimodal drug injection in bilateral simultaneous total knee arthroplasty: a randomized controlled trial	Osteoarthritis of knee, rheumatoid arthritis	A continuous epidural infusion containing ropivacaine and morphine for pain after simultaneous bilateral total knee arthroplasty A periarticular multimodal drug injection including ropivacaine, morphine, bosmin, methylprednisolone, and ketoprofen for pain after simultaneous bilateral total knee arthroplasty	Nekoyama miyao hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	60	Not selected	Japan
9	JPRN-UMIN000010902	2012/07/11	07/06/2013	A randomized controlled trial comparing epidural anesthesia and periarticular multimodal drug injection for total knee arthroplasty	A randomized controlled trial comparing epidural anesthesia and periarticular multimodal drug injection for total knee arthroplasty - A randomized controlled trial comparing epidural anesthesia and periarticular multimodal drug injection for total knee arthroplasty	Osteoarthritis of knee, rheumatoid arthritis, avascular necrosis	An epidural anesthesia containing 2mg/ml ropivacaine 100ml and 10mg/ml morphine 0.8ml for pain after total knee arthroplasty A periarticular multimodal drug injection including 7.5mg/ml ropivacaine, 10mg/ml morphine 0.8ml, bosmin 0.3mg, methylprednisolone 40mg, and ketoprofen 50mg for pain after total knee arthroplasty	Nekoyama miyao hospital	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	100	Not selected	Japan
10	NCT01382940 (ClinicalTrials.gov)	July 26, 2011	24/6/2011	A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis	A Multicenter, Open-label, Single-arm Study to Evaluate the Safety Administering Rituximab at a More Rapid Infusion Rate in Patients With Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: rituximab;Drug: methotrexate;Drug: methylprednisolone;Drug: acetaminophen;Drug: antihistamine	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	351	Phase 4	United States
11	NCT01390441 (ClinicalTrials.gov)	July 2011	7/7/2011	A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)	A Two-Part, Phase I Randomized, Double-Blind, Active-Comparator Controlled, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of MK-8808 and to Compare the Pharmacokinetics of MK-8808 With EU-approved MabThera® and US-licensed Rituxan® in Patients With Rheumatoid Arthritis (RA)	Rheumatoid Arthritis	Biological: MK-8808;Biological: MabThera® (rituximab);Drug: Methotrexate;Biological: Rituxan® (rituximab);Drug: Methylprednisolone;Drug: Acetaminophen;Drug: Loratadine	Merck Sharp & Dohme Corp.	NULL	Terminated	18 Years	65 Years	All	100	Phase 1	Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States
12	NCT01219933 (ClinicalTrials.gov)	January 2011	11/10/2010	A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)	An Open-label, Single-arm Study to Describe Glucocorticoid Use in Rheumatoid Arthritis Patients Treated With Tocilizumab in Daily Clinical Practice and to Evaluate Systematic Glucocorticoid Dose Reduction Once Low Disease Activity is Reached (ACT-ALONE)	Rheumatoid Arthritis	Drug: methylprednisolone;Drug: tocilizumab [RoActemra/Actemra]	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	68	Phase 4	Belgium
13	EUCTR2010-019694-15-BE (EUCTR)	28/09/2010	28/07/2010	Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoid dose reduction once low disease activity is reached - ACT-Alone	Act-Alone : An open-label, single-arm study to describe glucocorticoid use in rheumatoid arthritis patients treated with Tocilizumab in daily clinical practice and to evaluate systematic glucocorticoid dose reduction once low disease activity is reached - ACT-Alone	Rheumatoid Arthritis in adult MedDRA version: 13.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders	Trade Name: Medrol 4 mg tablets Other descriptive name: METHYLPREDNISOLONE Trade Name: Medrol A 16 mg tablets Other descriptive name: METHYLPREDNISOLONE	N.V. Roche S.A.	NULL	Not Recruiting			Female: yes Male: yes		Phase 4	Belgium
14	NCT00808210 (ClinicalTrials.gov)	March 5, 2009	11/12/2008	A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab	A PHASE II RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN COMBINATION WITH METHOTREXATE, COMPARED TO INFLIXIMAB PLUS METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS CURRENTLY RESPONDING INADEQUATELY TO ETANERCEPT OR ADALIMUMAB	Rheumatoid Arthritis	Drug: Infliximab;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Ocrelizumab;Drug: Placebo	Genentech, Inc.	NULL	Terminated	18 Years	N/A	All	28	Phase 2	United States
15	EUCTR2007-006150-25-DE (EUCTR)	09/01/2009	26/05/2008	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects with Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate - TRU-015	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: Prednisone Trade Name: Solu-Medrone 125mg INN or Proposed INN: Methylprednisolone Sodium Succinate Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: Prednisone Trade Name: Solu-Medrone 125mg INN or Proposed INN: Methylprednisolone Sodium Succinate	Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.	NULL	Not Recruiting			Female: yes Male: yes	216		Hungary;Germany;Serbia;Netherlands;Belgium;Mexico;France;Romania;Austria
16	EUCTR2007-006150-25-AT (EUCTR)	03/12/2008	07/10/2008	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	Rheumatoid Arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: PREDNISONE Trade Name: Solu-Medrone 125mg INN or Proposed INN: METHYLPREDNISOLONE Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: PREDNISONE Trade Name: Solu-Medrone 125mg INN or Proposed INN: METHYLPREDNISOLONE Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Wyeth Research Division of Wyeth Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	216		Hungary;Germany;Netherlands;Belgium;France;Austria
17	EUCTR2007-006150-25-NL (EUCTR)	01/12/2008	02/06/2008	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	Rheumatoid Arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: PREDNISONE Trade Name: Solu-Medrone 125mg Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: PREDNISONE Trade Name: Solu-Medrone 125mg Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Wyeth Research Division of Wyeth Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	216		Hungary;Germany;Netherlands;Belgium;France;Austria
18	EUCTR2007-006150-25-BE (EUCTR)	05/09/2008	24/06/2008	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	Rheumatoid Arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: PREDNISONE Trade Name: Solu-Medrone 125mg Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Wyeth Research Division of Wyeth Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	216	Phase 2	France;Hungary;Belgium;Austria;Netherlands;Germany
19	EUCTR2007-006150-25-HU (EUCTR)	04/07/2008	01/04/2009	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects with Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate - TRU-015	Rheumatoid Arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: Prednisone Trade Name: Solu-Medrone 125mg INN or Proposed INN: Methylprednisolone Sodium Succinate	Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.	NULL	Not Recruiting			Female: yes Male: yes	216		France;Serbia;Hungary;Mexico;Belgium;Romania;Austria;Netherlands;Germany
20	EUCTR2007-006150-25-FR (EUCTR)	24/06/2008	05/05/2008	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Stable Background of Methotrexate	Rheumatoid Arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: TRU-015 Trade Name: Decortin 5mg tablets INN or Proposed INN: PREDNISONE Trade Name: Solu-Medrone 125mg Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Wyeth Research Division of Wyeth Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	216	Phase 2	France;Hungary;Belgium;Austria;Netherlands;Germany
21	NCT01000610 (ClinicalTrials.gov)	March 17, 2008	21/10/2009	A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate	An Open Label Study to Evaluate the Safety and Efficacy of Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Prior Treatment With Methotrexate	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate;Drug: methylprednisolone	Hoffmann-La Roche	NULL	Completed	18 Years	N/A	All	18	Phase 4	Tunisia
22	NCT00634933 (ClinicalTrials.gov)	March 2008	5/3/2008	Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis	A Randomized, Parallel, Double-Blind, Placebo-Controlled Dose Regimen Finding Study To Evaluate The Safety And Efficacy Of TRU-015 In Subjects With Active Seropositive Rheumatoid Arthritis On A Stable Background Of Methotrexate	Arthritis, Rheumatoid	Drug: TRU-015;Drug: Methylprednisolone;Drug: Prednisone	Pfizer	Trubion Pharmaceuticals/Emergent BioSolutions Inc.	Terminated	18 Years	N/A	All	222	Phase 2	United States;Belgium;Canada;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;Austria
23	NCT00578305 (ClinicalTrials.gov)	November 2007	19/12/2007	A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate	A Randomized, Placebo Controlled, Multicenter Clinical Study Investigating Efficacy of Rituximab in the Inhibition of Joint Structural Damage Assessed by Magnetic Resonance Imaging in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate	Rheumatoid Arthritis	Biological: Rituximab;Drug: Placebo;Drug: Methylprednisolone;Drug: Methotrexate;Drug: Folic acid or folate	Hoffmann-La Roche	NULL	Completed	18 Years	80 Years	All	185	Phase 3	Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;Former Serbia and Montenegro;United Kingdom
24	EUCTR2006-005640-81-GB (EUCTR)	04/09/2007	27/07/2007	A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: - EXXTRA	A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: - EXXTRA	Rheumatoid arthritis	Trade Name: Mabthera Product Name: Mabthera Product Code: Rituximab Trade Name: Methylprednisolone Product Name: Methylprednisolone Other descriptive name: Methylprednisolone	University of Leeds	NULL	Not Recruiting			Female: yes Male: yes	60	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United Kingdom
25	EUCTR2007-001190-28-GB (EUCTR)	09/05/2007	17/04/2007	Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT	Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT	Rheumatoid Arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis	Product Name: Methotrexate Product Code: Methotrexate INN or Proposed INN: METHOTREXATE Product Name: Sulfasalazine Product Code: Sulfasalazine INN or Proposed INN: SULFASALAZINE Product Name: Hydroxychloroquine Product Code: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Product Name: Ciclosporin Product Code: Ciclosporin INN or Proposed INN: Ciclosporin Product Name: Leflunomide Product Code: Leflunomide INN or Proposed INN: Leflunomide Product Name: Sodium aurothiomalate (intramuscular gold) Product Code: Sodium aurothiomalate (intramuscular gold) INN or Proposed INN: Sodium aurothiomalate Product Name: methylprednisolone Product Code: methylprednisolone INN or Proposed INN: Methylprednisolone Product Name: Prednisolone Product Code: Predniso	King's College London	NULL	Not Recruiting			Female: yes Male: yes	190	Phase 4	United Kingdom
26	NCT01308255 (ClinicalTrials.gov)	September 2006	3/3/2011	Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)	A Multi-centre Randomised Double Blind Placebo Controlled Study Comparing Two Regimens of Combination Therapy in Early DMARD Naive Rheumatoid Arthritis.	Rheumatoid Arthritis	Drug: Infliximab;Drug: Methylprednisolone;Drug: Methotrexate;Dietary Supplement: Folic acid	University of Leeds	NULL	Completed	18 Years	80 Years	All	112	Phase 4	United Kingdom
27	NCT02006706 (ClinicalTrials.gov)	August 10, 2006	5/12/2013	A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy	An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure	Rheumatoid Arthritis	Drug: rituximab [MabThera/Rituxan];Drug: methotrexate;Drug: methylprednisolone	Hoffmann-La Roche	NULL	Completed	18 Years	80 Years	All	15	Phase 3	Serbia
28	NCT00298272 (ClinicalTrials.gov)	May 2006	1/3/2006	Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis	A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Biological: IDEC-C2B8 (rituximab);Drug: Placebo;Drug: Methotrexate;Drug: Etanercept;Drug: Adalimumab;Drug: Methylprednisolone;Dietary Supplement: Folate	Biogen	Hoffmann-La Roche;Genentech, Inc.	Terminated	18 Years	65 Years	All	54	Phase 2	United States
29	EUCTR2005-005013-37-GB (EUCTR)	06/04/2006	20/01/2006	A multi-centre randomised double dummy double blind study comparing two regimens of combination induction therapy in early DMARD naive Rheumatoid Arthritis: The IDEA study (Infliximab as Induction Therapy in Early Rheumatoid Arthritis) - IDEA	A multi-centre randomised double dummy double blind study comparing two regimens of combination induction therapy in early DMARD naive Rheumatoid Arthritis: The IDEA study (Infliximab as Induction Therapy in Early Rheumatoid Arthritis) - IDEA	Early Rheumatoid Arthritis	Trade Name: Remicade Product Name: Remicade Product Code: Infliximab Trade Name: Mextrex Product Name: Methotrexate Product Code: Mextrex INN or Proposed INN: n/a Other descriptive name: Methotrexate Trade Name: Ferrograd Folic Tablets Product Name: Folic Acid Product Code: Ferrograd INN or Proposed INN: n/a Other descriptive name: Folic Acid Trade Name: Solu-Medrone 2 Gram Product Name: Methylprednisolone Product Code: Solu-Medrone 2 Gram INN or Proposed INN: n/a Other descriptive name: Methylprednisolone Trade Name: Solu-Medrone 2 Gram Product Name: Methylprednisolone Product Code: Solu-Medrone 2 Gram INN or Proposed INN: n/a	University of Leeds	NULL	Not Recruiting			Female: yes Male: yes	112	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
30	EUCTR2005-004582-41-GB (EUCTR)	24/03/2006	27/01/2006	Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RA	Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RA	Active Rheumatoid Arthritis	Trade Name: Mabthera Product Name: Mabthera Product Code: Rituximab Trade Name: Arava Product Name: Arava Product Code: Leflunomide Trade Name: Solu-Medrone 2 Gram Product Name: Solu-Medrone 2mg Product Code: Methylprednisolone	University of Leeds	NULL	Not Recruiting			Female: yes Male: yes	15	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
31	NCT00299104 (ClinicalTrials.gov)	January 2006	2/3/2006	A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis	A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: folate;Drug: methotrexate;Drug: methylprednisolone;Drug: placebo;Drug: rituximab	Genentech, Inc.	Hoffmann-La Roche	Completed	18 Years	80 Years	All	755	Phase 3	United States
32	NCT00299130 (ClinicalTrials.gov)	October 2005	3/3/2006	A Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Active Rheumatoid Arthritis	A Randomized, Placebo Controlled, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate, Compared to Methotrexate Monotherapy, in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Folate;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Placebo;Drug: Rituximab	Genentech, Inc.	Hoffmann-La Roche	Completed	18 Years	80 Years	All	511	Phase 3	United States
33	NCT00241982 (ClinicalTrials.gov)	October 2005	18/10/2005	Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis	Long-Circulating Liposomal Prednisolone Versus Pulse Intramuscular Methylprednisolone in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: long-circulating liposomal prednisolone	Radboud University	Utrecht University	Completed	18 Years	N/A	Both	22	Phase 2	Netherlands
34	NCT00243412 (ClinicalTrials.gov)	August 2005	21/10/2005	A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate	A Double-Blind, Randomized, Multicenter, Phase II Study of the Safety and Efficacy of Two Rituximab Regimens in Subjects With Moderate to Severe Active Rheumatoid Arthritis Receiving Stable Doses of Methotrexate	Rheumatoid Arthritis	Drug: folate;Drug: methotrexate;Drug: methylprednisolone;Drug: Placebo;Drug: Rituximab	Genentech, Inc.	NULL	Completed	18 Years	65 Years	All	42	Phase 2	United States
35	NCT00396747 (ClinicalTrials.gov)	June 2003	6/11/2006	A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study	Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone	Rheumatoid Arthritis	Drug: Infliximab, methylprednisolone, methotrexate;Drug: Methotrexate;Drug: Methotrexate + Methylprednisolone;Drug: Methotrexate + Infliximab	Université Catholique de Louvain	NULL	Completed	18 Years	N/A	Both	45	Phase 4	Belgium
36	NCT02093026 (ClinicalTrials.gov)	August 2002	19/3/2014	Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)	An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: Rituximab;Drug: Methotrexate;Drug: Methylprednisolone;Drug: Folic Acid	Hoffmann-La Roche	Genentech, Inc.	Completed	21 Years	N/A	All	465	Phase 2	United States;Australia;Belgium;Brazil;Canada;Czech Republic;Finland;Germany;Israel;Italy;Mexico;New Zealand;Poland;Spain;Sweden;United Kingdom
37	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States

先頭へ

49. 全身性エリテマトーデス

臨床試験数 : 993 / 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05666336 (ClinicalTrials.gov)	December 31, 2022	8/12/2022	Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients	Proteomics Combined With Metabolomics Studies on the Efficacy of Telitacicept in Chinese Patients of Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Biological: Telitacicept;Drug: Hydroxychloroquine;Drug: Prednisone;Drug: Methylprednisolone;Drug: Cyclophosphamide;Drug: Mycophenolate Mofetil;Drug: Tacrolimus	Fen Li	NULL	Not yet recruiting	18 Years	75 Years	All	30	Phase 4	NULL
2	NCT04702256 (ClinicalTrials.gov)	December 9, 2021	30/11/2020	Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF	Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF	Lupus Nephritis;Systemic Lupus Erythematosus (SLE)	Drug: Obinutuzumab administration;Drug: Administration of Methylprednisolone + Prednisone + Mycophenolate mofetil;Drug: Administration of methylprednisolone, paracetamol and dexchlorpheniramine	Assistance Publique - Hôpitaux de Paris	Roche Pharma AG	Recruiting	14 Years	N/A	All	196	Phase 3	France
3	NCT04963296 (ClinicalTrials.gov)	October 26, 2021	7/7/2021	A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Obinutuzumab;Drug: Placebo;Drug: Acetaminophen/Paracetamol;Drug: Diphenhydramine hydrochloride;Drug: Methylprednisolone	Hoffmann-La Roche	NULL	Recruiting	18 Years	75 Years	All	200	Phase 3	United States;Argentina;Brazil;France;Italy;Mexico;New Zealand;Peru;Poland;Russian Federation;South Africa;Spain;United Kingdom
4	NCT03492255 (ClinicalTrials.gov)	April 12, 2018	16/3/2018	CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid	CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid	Systemic Lupus Erythematosus (SLE)	Drug: Cyclophosphamide;Drug: Methylprednisolone;Drug: Prednisone;Drug: Mycophenolate Mofetil	University of Sao Paulo General Hospital	Fundação de Amparo à Pesquisa do Estado de São Paulo	Terminated	18 Years	N/A	All	49	N/A	Brazil
5	NCT03054259 (ClinicalTrials.gov)	September 21, 2017	17/1/2017	Rituximab Objective Outcome Measures Trial in SLE	A Feasibility Randomised Placebo-controlled Trial With Objective Outcome Measures to Evaluate the Efficacy of Biosimilar Rituximab in Musculoskeletal and Mucocutaneous Systemic Lupus Erythematosus	Systemic Lupus Erythematosus Arthritis	Drug: Rituximab;Drug: Methylprednisolone;Drug: Normal Saline	University of Leeds	NULL	Recruiting	18 Years	99 Years	All	30	Phase 2	United Kingdom
6	ChiCTR-INR-17011495	2017-05-25	2017-05-26	Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic sy	The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of primary mild to moderate systemic systemic lupus erythematosus	Primary mild to moderate systemic systemic lupus erythematosus	Immunomodulatory treatment group:The level of SELSNA-SLEDAI was evaluated at week 4, week 12 and week 24, the BILAG table, the SLE lesion index, and the SLE damage index were measured at 4 weeks, 12 weeks and 24 weeks. The levels of Th17, Treg and Th17 / Treg were measured.;Leflunomide treatment group:Leflunomide tablets 10m, 1 times / day, orally. The SELSNA-SLEDAI score table, BILAG worksheet, SLE damage index score were assessed at week 4, week 12 and week 24, and serum Th17, Treg and Th17 / Treg ratios were measured.;Immunomodulatory treatment group and Leflunomide treatment group :0 weeks to give prednisone acetate tablets 0.5-1mg / kg.d (or patients can choose to take the same dose of methylprednisolone tablets), 4 weeks after the beginning of the dose by 2 weeks to reduce the regular dose of 10% Reduction to prednisone acetate tablets 10mg / day to maintain.;Immunomodulatory treatment group and Leflunomide treatment group:All patients without contraindications plus hydroxychloroquine tablets 0.2,2 / day, orally; and according to the condition plus calcium (800-1200mg / day), vitamin D (200-800IU / day) and other treatment.;	The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology	NULL	Recruiting			Both	Immunomodulatory treatment group:15;Leflunomide treatment group:15;Immunomodulatory treatment group and Leflunomide treatment group :30;Immunomodulatory treatment group and Leflunomide treatment group:30;		China
7	NCT03355482 (ClinicalTrials.gov)	April 10, 2017	22/11/2017	MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE	MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE	Systemic Lupus Erythematosus Arthritis	Drug: Methylprednisolone;Drug: Placebos	Oklahoma Medical Research Foundation	Bristol-Myers Squibb	Recruiting	18 Years	70 Years	All	40	Phase 2	United States
8	NCT02444728 (ClinicalTrials.gov)	July 2015	12/5/2015	Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE	Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus	Thrombocytopenia	Drug: Hydroxychloroquine;Drug: Cyclophosphamide;Drug: Azathioprine;Drug: Methylprednisolone	Chinese SLE Treatment And Research Group	Peking Union Medical College Hospital	Recruiting	18 Years	70 Years	All	220	Phase 3	China
9	NCT01085097 (ClinicalTrials.gov)	September 1, 2010	4/3/2010	A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis	A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids)	Lupus Nephritis	Drug: Laquinimod;Drug: Mycophenolate Mofetil;Drug: Prednisolone/Prednisone;Drug: Placebo;Drug: Methylprednisolone	Teva Branded Pharmaceutical Products R&D, Inc.	NULL	Completed	18 Years	75 Years	All	46	Phase 2	United States;Canada;France;Russian Federation;United Kingdom
10	NCT00539838 (ClinicalTrials.gov)	December 19, 2007	3/10/2007	A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)	A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus	Systemic Lupus Erythematosus	Drug: Prednisone;Drug: Immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate);Drug: Methylprednisolone;Drug: Ocrelizumab;Drug: Placebo	Genentech, Inc.	Roche Pharma AG	Terminated	16 Years	N/A	All	33	Phase 3	United States
11	NCT00381810 (ClinicalTrials.gov)	June 22, 2006	26/9/2006	A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus	An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g	Lupus Erythematosus, Systemic	Drug: Rituximab;Drug: Methylprednisolone;Drug: Acetaminophen;Drug: Diphenhydramine	Genentech, Inc.	NULL	Terminated	16 Years	75 Years	All	31	Phase 3	United States
12	EUCTR2005-003957-28-IT (EUCTR)	02/05/2006	09/05/2006	FIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. - ND	FIVE-YEAR SINGLE-BLIND, PHASE II EFFECTIVENESS RANDOMISED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS NEPHTRITIS ORAL CYCLOPHOSPHAMIDE VERSUS HIGH DOSE INTRAVENOUS CYCLOPHOSPHAMIDE VERSUS INTERMEDIATE DOSE INTRAVENOUS CYCLOPHOSPHAMIDE. - ND	New onset juvenile sistemic lupus erythematosus nephritis MedDRA version: 6.1;Level: PT;Classification code 10025140	INN or Proposed INN: Azathioprine INN or Proposed INN: Methylprednisolone INN or Proposed INN: Prednisone INN or Proposed INN: Cyclophosphamide INN or Proposed INN: Cyclophosphamide	ISTITUTO GIANNINA GASLINI	NULL	Not Recruiting			Female: yes Male: yes	141	Phase 3	Belgium;Denmark;Italy
13	JPRN-C000000159	2006/03/01	01/04/2006	Mizolibin for systemic lupus erythematosus in children(JSRDC10)	Mizolibin for systemic lupus erythematosus in children(JSRDC10) - Mizolibin for systemic lupus erythematosus in children(JSRDC10)	systematic lupus erythematosus	Methylprednisolone+mizoribine+prednisolone	Japanese Study Group of Renal Disease in Children(JSRDC)	NULL	Complete: follow-up complete	2years-old	18years-old	Male and Female	30	Not selected	Japan
14	NCT00076752 (ClinicalTrials.gov)	January 30, 2004	2/2/2004	Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus	A Pilot Study of Intensified Lymphodepletion Followed by Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Systemic Lupus Erythematosus	Lupus Erythematosus, Systemic	Drug: fludarabine phosphate;Drug: cyclophosphamide;Biological: Rituxan (rituximab);Biological: filgrastim;Drug: methylprednisolone;Other: immunologic technique;Other: laboratory biomarker analysis;Procedure: autologous hematopoietic stem cell transplantation;Drug: Diphenhydramine;Drug: Mesna	National Cancer Institute (NCI)	NULL	Completed	15 Years	40 Years	All	9	Phase 2	United States
15	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States
16	JPRN-C000000378	1995/03/01	01/04/2006	A combination of methylprednisoloneand prednisolone and a combination of Methylprednisolone, prednisolone and mizoribine for systemic lupus erythematosus in children: A randomized controlled trial of efficacy and safety izolibin for (JSRDC04)	A combination of methylprednisoloneand prednisolone and a combination of Methylprednisolone, prednisolone and mizoribine for systemic lupus erythematosus in children: A randomized controlled trial of efficacy and safety izolibin for (JSRDC04) - A combination of methylprednisolone and prednisolone and a combination of methylprednisolone, prednisolone and mizoribine: A randomized controlled trial (JSRDC04)	systematic lupus erythematosus	Methylprednisolone+prednisolone Methylprednisolone+prednisolone+mizoribine	Japanese Study Group of Renal Disease in Children(JSRDC)	NULL	Complete: follow-up complete	2years-old	18years-old	Male and Female	60	Not selected	Japan
17	EUCTR2005-003957-28-BE (EUCTR)		24/10/2006	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile systemic lupus erythematosus nephritis: oral cyclophosphamide versus high dose intravenous cyclophosphamide versus intermediate dose intravenous cyclophosphamide - PRINTO JSLE Trial	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile systemic lupus erythematosus nephritis: oral cyclophosphamide versus high dose intravenous cyclophosphamide versus intermediate dose intravenous cyclophosphamide - PRINTO JSLE Trial	Systemic lupus erythematosus nephritis	Product Name: Azathioprine INN or Proposed INN: Azathioprine Product Name: Methylprednisolone INN or Proposed INN: Methylprednisolone sodium succinate Product Name: Prednisolone INN or Proposed INN: Methylprednisolone Product Name: Cyclophosphamide INN or Proposed INN: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: Cyclophosphamide	University Hospital Gent	NULL	NA			Female: yes Male: yes	216	Phase 3	Belgium;Denmark;Italy

先頭へ

50. 皮膚筋炎／多発性筋炎

臨床試験数 : 194 / 薬物数 : 244 - (DrugBank : 89) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000032193	2018/04/11	13/04/2018	Efficacy and safety of combination therapy of corticosteroid and tacrolimus for patients with anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis-associated interstitial lung disease: a prospective multicenter clinical trial	Efficacy and safety of combination therapy of corticosteroid and tacrolimus for patients with anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis-associated interstitial lung disease: a prospective multicenter clinical trial - Combination therapy of corticosteroid and tacrolimus for anti-MDA5 antibody-positive DM-ILD	anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis (DM)/clinically amyopathic dermatomyositis (CADM)-associated interstitial lung disease	Patients without poor prognostic factors: combination therapy of corticosteroid (prednisolone) and tacrolimus for 12 months Initial dose of oral prednisolone is 0.7 - 1mg/kg/day (Maximum dose of prednisolone is 60mg/body/day). Intravenous methylprednisolone pulse therapy (0.5 - 1g/day for 3 days) is permitted according to the initial disease activity. After 4 weeks of initial treatment, prednisolone is tapered by approximately 10 to 20% every 2 to 4 weeks and continued at dose of 0.125 mg/kg/day or more in the study period (12 months). Tacrolimus is administered orally at initial dose of 0.075 mg/kg/day (twice daily) and adjusted over time to maintain a whole-blood trough level of 5 - 10 ng/ml. For patients with poor prognostic factors, attending physician can chose any treatments (e.g. corticosteroid, immunosuppressant, IVIG). The patients were followed up for 12 months.	Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine	NULL	Recruiting	20years-old	80years-old	Male and Female	40	Not selected	Japan
2	JPRN-UMIN000032022	2018/04/01	01/04/2018	Efficacy and safety of corticosteroid monotherapy versus combination therapy of corticosteroid and tacrolimus for patients with anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a prospective randomized multicenter clinical trial	Efficacy and safety of corticosteroid monotherapy versus combination therapy of corticosteroid and tacrolimus for patients with anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a prospective randomized multicenter clinical trial - Corticosteroid monotherapy versus combination therapy of corticosteroid and tacrolimus for anti-ARS antibody-positive PM/DM-ILD	anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis/clinically amyopathic dermatomyositis-associated interstitial lung disease	Arm 1: corticosteroid (prednisolone) monotherapy for 24 months Initial dose of oral prednisolone is 0.7 - 1mg/kg/day. (Maximum dose of prednisolone is 60mg/body/day.) Intravenous methylprednisolone pulse therapy (0.5 - 1g/day for 3 days) is permitted according to the initial disease activity. After 4 weeks of initial treatment, prednisolone is tapered by approximately 10 to 20% every 2 to 4 weeks (from 1 to 9 month) and continued at dose of 0.125 - 0.15 mg/kg/day or more (from 9 to 12 month) or 0.1 - 0.125 mg/kg/day or more (from 12 to 24 month). Arm 2: combination therapy of corticosteroid (prednisolone) and tacrolimus for 24 months Initial dose of oral prednisolone is 0.7 - 1mg/kg/day. (Maximum dose of prednisolone is 60mg/body/day.) Intravenous methylprednisolone pulse therapy (0.5 - 1g/day for 3 days) is permitted according to the initial disease activity. After 4 weeks of initial treatment, prednisolone is tapered by approximately 10 to 20% every 2 to 4 weeks (from 1 to 9 month) and continued at dose of 0.125 - 0.15 mg/kg/day or more (from 9 to 12 month) or 0.1 - 0.125 mg/kg/day or more (from 12 to 24 month). Tacrolimus is administered orally at initial dose of 0.075 mg/kg/day (twice daily) and adjusted over time to maintain a whole-blood trough level of 5 - 10 ng/ml.	Hamamatsu University School of Medicine	NULL	Recruiting	20years-old	80years-old	Male and Female	66	Not selected	Japan
3	JPRN-UMIN000015469	2014/10/20	18/10/2014	Comparison of efficacy between tacrolimus and cyclosporine for the treatment of polymyositis/dermatomyositis-associated interstitial lung disease	Comparison of efficacy between tacrolimus and cyclosporine for the treatment of polymyositis/dermatomyositis-associated interstitial lung disease - Comparison between tacrolimus and cyclosporine for the treatment of PM/DM-ILD	polymyositis/dermatomyositis/clinically amyopathic dermatomyositis-associated Interstitial lung disease	arm1: tacrolimus and predonisolon therapy for 52 weeks Initial dose of oral prednisolone is 0.6 - 1 mg/kg/day. Intravenous methylprednisolone pulse therapy (1 g/day for 3 days) is permitted according to the disease activity. After 4 weeks of initial treatment, prednisolone was tapered by approximately 10 to 20% every 2 to 4 weeks and continued at dose of 0.125 mg/kg/day or more. Taclorimus is administered orally at initial dose of 0.075 mg/kg/day (twice daily) and adjusted over time to maintain a whole-blood trough level of 5 - 10 ng/ml. arm2: cyclosporine and predonisolone therapy for 52 weeks Initial dose of oral prednisolone is 0.6 - 1 mg/kg/day. Intravenous methylprednisolone pulse therapy (1 g/day for 3 days) is permitted according to the disease activity. After 4 weeks of initial treatment, prednisolone was tapered by approximately 10 to 20% every 2 to 4 weeks and continued at dose of 0.125 mg/kg/day or more. Cyclosporine is administered orally at initial dose of 3 mg/kg/day (twice daily before meal) and adjusted over time to maintain a whole-blood trough level of 100 - 150 ng/ml.	Second Division, Department of Internal medicine, Hamamatsu University School of Medicine	NULL	Complete: follow-up complete	18years-old	75years-old	Male and Female	50	Not selected	Japan
4	ChiCTR-TRC-13003178	2013-05-01	2013-01-03	Study of Treatment Approaches in Myositis (STRAIM): a prospective, multicenter, randomized and open label clinical study	Study of Treatment Approaches in Myositis (STRAIM): a prospective, multicenter, randomized and open label clinical study	Polymyositis/Dermatomyositis	group1-predinsone group(control group):Prednisone 1mg/kg/d (or eaqual dose prednisolone/ methylprednisolone)×6-8 weeks, biweekly reduction 5 mg to 30mg / d, then reduce 2.5mg every two weeks to 5mg/d, maintenance therapy to 72 weeks; seriously ill patient can consider the impact of initial methyl prednisolone 0.5-1.0g/d treatment×3days.;group1-predinsone+MTX group:MTX 10-20mgQw×24w; MTX 7.5-10mgQw×48w, the usage of prednisone is the same as in the control group.;group1-predinsone+LEF group:LEF 20mg/d×24w; LEF 10mg/d×48w, the usage of prednisone is the same as in the control group.;group2-predinsone group(control group):Prednisone 1mg/kg/d (or eaqual dose prednisolone/ methylprednisolone)×6-8 weeks, biweekly reduction 5 mg to 30mg/d, then reduce 2.5mg every two weeks to 5mg/d,maintenance therapy to 72 weeks; seriously ill patient can consider the impact of initial methyl prednisolone 0.5-1.0g/d treatment×3days.;group2-predinsone+CTX group:CTX iv 0.8-1.0g/4w×24w; CTX iv 0.8-1.0g/12w×48w, the usage of prednisone is the same as in the control group.;group2-predinsone+MTX group:MMF 1.5-2.0g /d×24w; MMF 0.75-1g/d×48w, the usage of prednisone is the same as in the control group.;	Department of rheumatology, China-Japan Friendship hospital	NULL	Recruiting	18	70	Both	group1-predinsone group(control group):94;group1-predinsone+MTX group:94;group1-predinsone+LEF group:94;group2-predinsone group(control group):94;group2-predinsone+CTX group:94;group2-predinsone+MTX group:94;		China
5	JPRN-UMIN000001866	2009/04/01	10/04/2009	Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis	Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis - Continuous intravenous infusion therapy with cyclosporine A for rapidly progressive interstitial pneumonia associated with dermatomyositis and polymyositis	Dermatomyositis or polymyositis with interstitial pneumonia	(1)The patients are initially treated with methylprednisolone (m-PSL) pulse (1000 mg daily for three days) followed by oral prednisolone (1mg/kg daily). (2)Continuous intravenous CyA (2 mg/kg daily for initial dose) is started following m-PSL pulse therapy, and the dosage will be adjusted to a level of 200-300ng/ml.	Department of Neurology and Rheumatology, Shinshu University School of Medicine	NULL	Complete: follow-up complete	16years-old	Not applicable	Male and Female	10	Not selected	Japan
6	EUCTR2005-003956-37-GB (EUCTR)	18/06/2008	20/03/2008	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisolone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisolone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Juvenile Dermatomyositis at onset	Trade Name: treatment defined only by active substance Product Name: prednisone Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methylprednisolone Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methotrexate Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methotrexate Product Code: not available INN or Proposed INN: not availa	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
7	EUCTR2005-003956-37-SE (EUCTR)	23/02/2007	11/12/2006	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Juvenile Dermatomyositis at onset	Trade Name: treatment defined only by active substance Product Name: Prednisone Product Code: Not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: methylprednisolone Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: Cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: not available Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: Cyclosporine A Product Code: not available INN or Proposed INN: not available Other descriptive name: not available Trade Name: treatment defined only by active substance Product Name: Methotrexate Product Code: not available	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
8	EUCTR2005-003956-37-BE (EUCTR)	13/11/2006	25/10/2006	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate - PRINTO JDM Trial	Five year single blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate - PRINTO JDM Trial	Juvenile Dermatomyositis at onset	Product Name: Prednisolone INN or Proposed INN: Methylprednisolone Product Name: Methylprednisolone INN or Proposed INN: Methylprednisolone sodium succinate Product Name: Cyclosporine INN or Proposed INN: Cyclosporine A Product Name: Cyclosporine INN or Proposed INN: Cyclosporine A Product Name: Methotrexate INN or Proposed INN: Methotrexate Product Name: Methotrexate INN or Proposed INN: Methotrexate	University Hospital Gent	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	180	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
9	EUCTR2005-003956-37-DK (EUCTR)	03/11/2006	15/09/2006	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine A versus prednisone plus methotrexate	Juvenile Dermatomyositis at onset	Product Name: Prednisone Product Name: methylprednisolone Product Name: Cyclosporine Product Name: Cyclosporine Product Name: Cyclosporine Product Name: Metotrexate Product Name: Methotrexate	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	Belgium;Denmark;Netherlands;United Kingdom;Italy;Sweden
10	EUCTR2005-003956-37-NL (EUCTR)	26/09/2006	01/06/2006	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis:prednisone versus prednisone plus cyclosporine A versus prednisone plus mehotrexate	Five year single-blind, phase III effectiveness randomised actively controlled clinical trial in new onset juvenile dermatomyositis:prednisone versus prednisone plus cyclosporine A versus prednisone plus mehotrexate	Juvenile Dermatomyositis at onset	INN or Proposed INN: Prednisone INN or Proposed INN: Methylprednisolone INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Methotrexate INN or Proposed INN: Methotrexate	Istituto Giannina Gaslini	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	160	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
11	EUCTR2005-003956-37-IT (EUCTR)	02/05/2006	12/09/2006	FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE PLUS METHOTREXATE - ND	FIVE-YEAR SINGLE-BLIND, PHASE III EFFECTIVENESS RANDOMIZED ACTIVELY CONTROLLED CLINICAL TRIAL IN NEW ONSET JUVENILE DERMATOMYOSITIS PREDNISONE VERSUS PREDNISONE PLUS CYCLOSPORINE A VERSUS PREDNISONE PLUS METHOTREXATE - ND	New Onset juvenile dermatomyositis MedDRA version: 6.1;Level: PT;Classification code 10012503	INN or Proposed INN: Prednisone INN or Proposed INN: Methylprednisolone INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Ciclosporin INN or Proposed INN: Methotrexate INN or Proposed INN: Methotrexate	ISTITUTO GIANNINA GASLINI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	132	Phase 3	United Kingdom;Netherlands;Belgium;Italy;Sweden
12	NCT00004357 (ClinicalTrials.gov)	September 1997	18/10/1999	Absorption of Corticosteroids in Children With Juvenile Dermatomyositis	Phase II Study of Prednisolone/Methylprednisolone Absorption in Children With Juvenile Dermatomyositis	Vasculitis, Hypersensitivity;Connective Tissue Diseases;Dermatomyositis;Vasculitis	Drug: Methylprednisolone;Drug: Prednisolone	Northwestern University	Ann & Robert H Lurie Children's Hospital of Chicago	Completed	4 Years	21 Years	Both	6	Phase 2	United States

先頭へ

51. 全身性強皮症

臨床試験数 : 525 / 薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2015-004613-24-BE (EUCTR)	17/07/2019	18/04/2019	Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized explorative double-blind placebo-controlled trial.	Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized explorative double-blind placebo-controlled trial. - Hit hard and early	(very early) systemic sclerosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Solu-Medrol Product Name: methylprednisolon INN or Proposed INN: METHYLPREDNISOLONE SODIUM SUCCINATE Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 4	Belgium;Netherlands
2	NCT03742466 (ClinicalTrials.gov)	November 10, 2018	10/11/2018	Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients	Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients. A Single-blind Randomized Clinical Trial	Carpal Tunnel Syndrome;Chronic Pain;Scleroderma	Drug: Ozone;Drug: methylprednisolone acetate	Assiut University	NULL	Completed	20 Years	60 Years	All	50	N/A	Egypt
3	NCT03593902 (ClinicalTrials.gov)	May 17, 2018	28/6/2018	Cardiac Safe Transplants for Systemic Sclerosis	Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction	Systemic Sclerosis;Scleroderma	Drug: Rituximab;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University	NULL	Terminated	18 Years	65 Years	All	9	Phase 2/Phase 3	United States
4	NCT03059979 (ClinicalTrials.gov)	January 2017	25/1/2017	The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )	Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial.	Systemic Sclerosis;Raynaud Phenomena	Drug: Methylprednisolone;Other: sodium chloride	Radboud University	NULL	Recruiting	18 Years	N/A	All	30	Early Phase 1	Netherlands
5	EUCTR2015-004613-24-NL (EUCTR)	30/05/2016	13/04/2016	Hit hard and early	Hit hard and early. The effect of high dose methylprednisolon on nailfold capillary changes and biomarkers in early SSc: a 12-week randomized double-blind placebo-controlled trial. - Hit hard and early	(very early) systemic sclerosis;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: methylprednisolon INN or Proposed INN: methylprednisolon Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Radboudumc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 4	Netherlands
6	NCT01445821 (ClinicalTrials.gov)	September 15, 2011	29/9/2011	Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial	Randomized Study of Different Non-myeloablative Conditioning Regimens With Hematopoietic Stem Cell Support in Patients With Scleroderma (Autologous Systemic Sclerosis Immune Suppression Trial - II ASSIST-IIb)	Scleroderma, Systemic	Biological: Peripheral Blood Stem Cells;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: Filgrastim;Drug: Fludarabine	Northwestern University	NULL	Terminated	17 Years	60 Years	All	44	Phase 3	United States
7	NCT01086540 (ClinicalTrials.gov)	June 24, 2011	11/3/2010	Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)	A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)	Systemic Sclerosis-Associated PAH	Biological: Rituximab;Other: Placebo;Diagnostic Test: CMRI;Drug: prednisone;Drug: methylprednisolone;Drug: diphenhydramine;Drug: acetaminophen	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Completed	18 Years	75 Years	All	57	Phase 2	United States
8	EUCTR2006-004598-83-GB (EUCTR)	22/10/2008	24/10/2008	High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis ( ‘ASTIS’-TRIAL: Autologous Stem Cell Transplantation International Scleroderma Trial) - ASTIS	High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis ( ‘ASTIS’-TRIAL: Autologous Stem Cell Transplantation International Scleroderma Trial) - ASTIS	Severe systemic sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10042953;Term: Systemic sclerosis	Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade Name: Neupogen Product Name: Filgrastim INN or Proposed INN: FILGRASTIM Trade Name: Thymoglobuline Product Name: Thymoglobuline Product Code: rbATG INN or Proposed INN: Anti-Thymocyte Globulin, Rabbit Other descriptive name: ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS Trade Name: Solu-Medrone Product Name: Methylprednisolone INN or Proposed INN: METHYLPREDNISOLONE Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE Trade Name: Mesna Product Name: Mesna INN or Proposed INN: MESNA Trade Name: Mesna Product Name: Mesna INN or Proposed INN: MESNA	EBMT (European group for Blood and Marrow Transplantation)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150		United Kingdom
9	EUCTR2008-000224-27-GB (EUCTR)	15/10/2008	07/08/2008	Systemic sclerosis associated interstitial lung disease: A longitudinal observational study assessing optimum treatment regimens. - Assessment of scleroderma lung disease	Systemic sclerosis associated interstitial lung disease: A longitudinal observational study assessing optimum treatment regimens. - Assessment of scleroderma lung disease	Systemic Sclerosis associated interstitial lung disease MedDRA version: 9.1;Level: LLT;Classification code 10042953;Term: Systemic sclerosis	Trade Name: Solu-medrone Product Name: methylprednisolone INN or Proposed INN: METHYLPREDNISOLONE Product Name: cyclophosphamide Product Code: cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE	Newcastle upon Tyne NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 4	United Kingdom
10	NCT00379431 (ClinicalTrials.gov)	November 27, 2006	20/9/2006	A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab	A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab	Early and Severe Systemic Sclerosis	Drug: Administration of rituximab and methylprednisolone	University Hospital, Ghent	NULL	Completed	18 Years	N/A	All	9	Phase 2	Belgium

先頭へ

60. 再生不良性貧血

臨床試験数 : 245 / 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs071190032	26/11/2019	21/10/2019	W-JHS AA02	Investigation on the effectiveness of rabbit ATG + cyclosporine + eltrombopag therapy for patients with aplastic anemia - W-JHS AA02	aplastic anemia	1. The administration of rATG; 2.5 mg/kg, iv. daily, day 1 - day 5 + CsA; 5 mg/kg, po. bid (before breakfast and before dinner) +adrenalcorticosteroid (the dose is mentioned after) is started. CsA used is Neoral or generic drug emulsified in the same way with Neoral. A blood level of CsA is measured and the dose which CsA blood level 2 hours after oral administration (C2) reachs 600 - 900 ng/mL is adjusted. The investigator shall reduce the dose of CsA by 25% on this occasion when blood trough level (C0) just before the administration is beyond 250 ng/mL because renal function disorder may occur (2). When serum creatinine level also becomes higher than 150% of baselines, the 25% dose reduction of CsA shall be performed. If C2 did not reach to 600 ng/mL, then dose of CsA is appropriately increased. 2. EPAG; 75 mg, po. daily (before sleep, requires to pass more than at least 2 hours after dinner) is started from day 6. 3. The dose of steroid is as follows: Day 1 - day 5: methylprednisolone 2 mg/kg/day Day 6: Methylprednisolone 1 mg/kg/day Day 8, 10, 12, 14, 16, 18, 20: prednisolone 0.5 mg/kg/day Discontinuation after day 21 4. The administration of CsA and EPAG is continued for 26 weeks. When it passed 26 weeks, further treatment mentioned above is entrusted to the investigator in each medical institution after 27 weeks if patients reached Camitta criteria CR or PR. However, the administration is continued for 52 weeks even if the dose of CsA is reduced. The treatment after 53 weeks is not specified. If patients did not reach CR or PR at 26 weeks, treatment after 27 weeks is entrusted to the investigator in each medical institution (it is not specified in this study).	Ishiyama Ken	NULL	Recruiting	>= 18age old	< 80age old	Both	60	Phase 2	Japan
2	NCT03579875 (ClinicalTrials.gov)	November 13, 2018	25/5/2018	T Cell Receptor a/ß TCD HCT in Patients With Fanconi Anemia	T Cell Receptor Alpha/Beta T Cell Depleted (a/ß TCD) Hematopoietic Cell Transplantation in Patients With Fanconi Anemia (FA)	Fanconi Anemia;Severe Aplastic Anemia;Myelodysplastic Syndromes	Drug: Total Body Irradiation (TBI) (Plan 1);Drug: Cyclophosphamide (CY) (Plan 1);Drug: Fludarabine (FLU);Drug: Methylprednisolone (MP);Device: Donor mobilized PBSC infusion;Drug: G-CSF;Drug: Cyclophosphamide (CY) (Plan 2);Drug: Rituximab;Drug: Busulfan	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	65 Years	All	48	Phase 2	United States
3	NCT02462252 (ClinicalTrials.gov)	October 2015	25/5/2015	Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome	A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)	Aplastic Anemia;Hypoplastic Myelodysplastic Syndrome	Drug: BL-8040;Drug: horse anti-thymocyte globulin (hATG);Drug: Methylprednisolone;Drug: Cyclosporine	BioLineRx, Ltd.	NULL	Recruiting	18 Years	N/A	All	25	Phase 2	United States
4	NCT01624805 (ClinicalTrials.gov)	June 25, 2012	19/6/2012	Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome	Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)	Aplastic Anemia;de Novo Myelodysplastic Syndrome;Myelodysplastic Syndrome;Previously Treated Myelodysplastic Syndrome	Biological: Anti-Thymocyte Globulin;Drug: Cyclosporine;Biological: Filgrastim;Drug: Methylprednisolone;Biological: Pegfilgrastim	M.D. Anderson Cancer Center	National Cancer Institute (NCI)	Recruiting	N/A	N/A	All	100	Phase 2	United States
5	NCT00455312 (ClinicalTrials.gov)	August 2007	30/3/2007	Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA	Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia	Dyskeratosis Congenita;Aplastic Anemia	Drug: Campath 1H;Drug: Cyclophosphamide;Drug: Fludarabine;Procedure: Total Body Irradiation;Procedure: Stem Cell Transplantation;Drug: antithymocyte globulin;Drug: Methylprednisolone	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	70 Years	All	36	Phase 2/Phase 3	United States
6	NCT00806598 (ClinicalTrials.gov)	May 2005	9/12/2008	Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome	Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome	Myelodysplastic Syndrome;Aplastic Anemia	Drug: Thymoglobulin;Drug: Cyclosporine;Drug: Methylprednisolone;Drug: G-CSF	M.D. Anderson Cancer Center	Genzyme, a Sanofi Company	Completed	15 Years	N/A	All	53	Phase 2	United States
7	NCT00054236 (ClinicalTrials.gov)	May 2002	5/2/2003	Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia	Pilot Study Of Multiple Umbilical Cord Blood Unit Transplantation Following Non-Myeloablative Conditioning In Patients With Hematologic Disorders Or Severe Aplastic Anemia	Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases	Biological: anti-thymocyte globulin;Biological: filgrastim;Drug: cyclophosphamide;Drug: fludarabine phosphate;Procedure: umbilical cord blood transplantation;Drug: methylprednisolone	Case Comprehensive Cancer Center	NULL	Completed	N/A	120 Years	All	55	Phase 1	United States
8	NCT00053989 (ClinicalTrials.gov)	January 29, 2002	5/2/2003	NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders	Non-Myeloablative Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Disorders	Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases;Fanconi Anemia;Aplastic Anemia	Biological: anti-thymocyte globulin;Biological: graft-versus-tumor induction therapy;Biological: sargramostim;Biological: therapeutic allogeneic lymphocytes;Drug: cyclophosphamide;Drug: fludarabine phosphate;Drug: methylprednisolone;Drug: mycophenolate mofetil;Drug: tacrolimus;Procedure: allogeneic bone marrow transplantation;Procedure: peripheral blood stem cell transplantation;Procedure: umbilical cord blood transplantation	Roswell Park Cancer Institute	NULL	Completed	4 Years	75 Years	All	41	Phase 2	United States
9	NCT00017654 (ClinicalTrials.gov)	April 2001	6/6/2001	Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia		Graft Versus Host Disease;Aplastic Anemia	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: methylprednisolone;Procedure: Allogeneic Bone Marrow Transplantation	Northwestern Memorial Hospital	NULL	Active, not recruiting	15 Years	55 Years	Both	3	N/A	United States
10	NCT00003336 (ClinicalTrials.gov)	January 1998	1/11/1999	Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions	A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders	Leukemia;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases	Biological: anti-thymocyte globulin;Drug: busulfan;Drug: cyclophosphamide;Drug: melphalan;Drug: methylprednisolone;Procedure: bone marrow ablation with stem cell support;Procedure: umbilical cord blood transplantation;Radiation: radiation therapy	Case Comprehensive Cancer Center	National Cancer Institute (NCI)	Completed	N/A	55 Years	Both	6	Phase 2	United States
11	NCT00005852 (ClinicalTrials.gov)	June 1996	2/6/2000	Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant	Allogeneic Bone Marrow Transplantation for Marrow Failure States	Chronic Myeloproliferative Disorders;Graft Versus Host Disease;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes	Biological: anti-thymocyte globulin;Biological: filgrastim;Biological: muromonab-CD3;Drug: cyclophosphamide;Drug: cyclosporine;Drug: methylprednisolone;Procedure: allogeneic bone marrow transplantation	H. Lee Moffitt Cancer Center and Research Institute	National Cancer Institute (NCI)	Terminated	15 Years	55 Years	Both		Phase 2	NULL
12	NCT00002718 (ClinicalTrials.gov)	November 1995	1/11/1999	T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia	A Phase II Trial of T-Cell Depleted Marrow Grafts Combined With Infusions of G-CSF Stimulated, CD34 Ceprate Stem Cell Column Selected, E-Rosette Depleted Peripheral Blood Progenitor Cells Derived From HLA Haplotype Matched Related Donors for Patients With Leukemia Lacking an HLA-Matched Related or Unrelated Donor	Leukemia;Lymphoma;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Neoplasms	Biological: anti-thymocyte globulin;Biological: filgrastim;Drug: cyclophosphamide;Drug: cytarabine;Drug: methylprednisolone;Drug: thiotepa;Procedure: in vitro-treated bone marrow transplantation;Procedure: in vitro-treated peripheral blood stem cell transplantation;Radiation: radiation therapy	Memorial Sloan Kettering Cancer Center	National Cancer Institute (NCI)	Completed	N/A	49 Years	Both	31	Phase 2	United States
13	NCT00004323 (ClinicalTrials.gov)	February 1995	18/10/1999	Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia		Aplastic Anemia	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: mesna;Drug: methotrexate;Drug: methylprednisolone	National Center for Research Resources (NCRR)	University of California, Los Angeles	Completed	N/A	55 Years	Both	10	Phase 2	United States

先頭へ

62. 発作性夜間ヘモグロビン尿症

臨床試験数 : 292 / 薬物数 : 151 - (DrugBank : 49) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 108

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000039675	2021-01-01	2020-11-05	Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal nocturnal hemoglobinuria	Phase II clinical trial of the superiority of all-trans retinoic acid in the treament of paroxysmal nocturnal hemoglobinuria	paroxysmal nocturnal hemoglobinuria	experimental group:Tretinoin 0.33mg/kg.d; methylprednisolone 0.8mg/kg.d;Control test:methylprednisolone 0.8mg/kg.d;	Department of Hematology, Second Medical Center, Chinese PLA General Hospital	NULL	Recruiting	14	80	Both	experimental group:10;Control test:10;	Phase 2	Chinese

63. 特発性血小板減少性紫斑病

臨床試験数 : 391 / 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004103-12-IT (EUCTR)	24/07/2020	21/01/2021	A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune Thrombocytopenia	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia - /	Primary immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10050245;Term: Autoimmune thrombocytopenia;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]	Product Name: TAK-079 Product Code: [TAK-079] INN or Proposed INN: TAK-079 Product Name: difenidramina Product Code: [NA] INN or Proposed INN: DIFENIDRAMINA CLORIDRATO Other descriptive name: dyphenhydramine hydrochloride Product Name: paracetamolo Product Code: [acetominofene] INN or Proposed INN: PARACETAMOLO Other descriptive name: acetominophen Product Name: metilprednisolone Product Code: [/] INN or Proposed INN: METILPREDNISOLONE Other descriptive name: methylprednisolone	MILLENNIUM PHARMACEUTICALS, INC.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	54	Phase 2	United States;Slovenia;Ukraine;Croatia;Bulgaria;Germany;Italy
2	ChiCTR-IIR-16008994	2016-09-01	2016-08-08	Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trial	Safety and efficacy analysis of two conventional dosage regimens Methylprednisone for initial treatment of primary immune thrombocytopenia:A multicenter randomized controlled clinical trial	Primary immune thrombocytopenia	the short-course group (Group A):Oral methylprednisolone for 2 weeks, the initial dosage is 0.8mg/kg/d, than reduces to 0.4mg/kg/d for 1 week, than to 0.2mg/kg/d for 1 week, than stop.;the long-course treatment group (Group B):Oral methylprednisolone for 1 month, the initial dosage is 0.8mg/kg/d,than reduces to 0.4mg/kg/d for 1 month, than to 0.1mg/kg/d for 2 week, than stop.;	Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College	NULL	Pending	18	60	Both	the short-course group (Group A):150;the long-course treatment group (Group B):150;	4 (Phase 4 study)	China

64. 血栓性血小板減少性紫斑病

臨床試験数 : 92 / 薬物数 : 85 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 76

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04074187 (ClinicalTrials.gov)	October 21, 2019	14/8/2019	A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)	An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura	Thrombotic Thrombocytopenic Purpura	Drug: Caplacizumab (ALX-0081);Drug: Plasma exchange (PE);Drug: Corticosteroid treatment (Methylprednisolone or prednisolone);Drug: Immunosuppressive treatment (eg, rituximab)	Sanofi	NULL	Completed	18 Years	N/A	All	21	Phase 2/Phase 3	Japan

65. 原発性免疫不全症候群

臨床試験数 : 500 / 薬物数 : 614 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01220531 (ClinicalTrials.gov)	November 8, 2010	22/9/2010	Thymus Transplantation Safety-Efficacy	Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836	Complete DiGeorge Anomaly;DiGeorge Syndrome;DiGeorge Anomaly;Complete DiGeorge Syndrome	Biological: Cultured Thymus Tissue;Procedure: Blood Draw;Drug: Rabbit anti-thymocyte globulin;Drug: Cyclosporine;Drug: Tacrolimus;Drug: Methylprednisolone or Prednisolone;Drug: Mycophenolate mofetil	M. Louise Markert	National Institutes of Health (NIH);National Institute of Allergy and Infectious Diseases (NIAID);Enzyvant Therapeutics GmbH	Available	N/A	N/A	All			United States
2	NCT00455312 (ClinicalTrials.gov)	August 2007	30/3/2007	Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA	Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia	Dyskeratosis Congenita;Aplastic Anemia	Drug: Campath 1H;Drug: Cyclophosphamide;Drug: Fludarabine;Procedure: Total Body Irradiation;Procedure: Stem Cell Transplantation;Drug: antithymocyte globulin;Drug: Methylprednisolone	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	70 Years	All	36	Phase 2/Phase 3	United States
3	NCT00579527 (ClinicalTrials.gov)	December 19, 2005	20/12/2007	Phase I/II Thymus Transplantation With Immunosuppression #950	Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950	DiGeorge Anomaly;Complete DiGeorge Anomaly;Complete Atypical DiGeorge Anomaly;Complete DiGeorge Syndrome;Complete Atypical DiGeorge Syndrome	Biological: Cultured Thymus Tissue for Implantation (CTTI);Other: Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation;Procedure: Blood Draw;Drug: Rabbit anti-thymocyte globulin;Drug: Cyclosporine;Drug: Tacrolimus;Drug: Methylprednisolone or Prednisolone;Drug: Daclizumab;Drug: Mycophenolate mofetil	Enzyvant Therapeutics GmBH	National Institutes of Health (NIH);National Institute of Allergy and Infectious Diseases (NIAID);Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	N/A	N/A	All	14	Phase 1/Phase 2	United States
4	NCT00301834 (ClinicalTrials.gov)	January 2005	9/3/2006	Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders	Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia	Congenital Amegakaryocytic Thrombocytopenia;Diamond-blackfan Anemia;Leukemia;Myelodysplastic Syndromes;Severe Congenital Neutropenia	Biological: alemtuzumab;Drug: busulfan;Drug: cyclosporine;Drug: fludarabine phosphate;Drug: methotrexate;Drug: methylprednisolone;Procedure: allogeneic bone marrow transplantation;Procedure: allogeneic hematopoietic stem cell transplantation;Procedure: peripheral blood stem cell transplantation;Procedure: umbilical cord blood transplantation	University of California, San Francisco	National Cancer Institute (NCI)	Completed	N/A	21 Years	All	35	Phase 2	United States
5	NCT00006054 (ClinicalTrials.gov)	March 2000	5/7/2000	Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies		Immunologic Deficiency Syndromes;Chediak-Higashi Syndrome;Common Variable Immunodeficiency;Graft Versus Host Disease;X-Linked Lymphoproliferative Syndrome;Familial Erythrophagocytic Lymphohistiocytosis;Hemophagocytic Lymphohistiocytosis;X-linked Agammaglobulinemia;Wiskott-Aldrich Syndrome;Chronic Granulomatous Disease;X-linked Hyper IgM Syndrome;Severe Combined Immunodeficiency;Leukocyte Adhesion Deficiency Syndrome;Virus-Associated Hemophagocytic Syndrome	Drug: anti-thymocyte globulin;Drug: busulfan;Drug: cyclophosphamide;Drug: cyclosporine;Drug: etoposide;Drug: methotrexate;Drug: methylprednisolone;Drug: prednisone;Procedure: Allogeneic Bone Marrow Transplantation	Fairview University Medical Center	NULL	Terminated	N/A	35 Years	Both		N/A	United States

先頭へ

66. IgA腎症

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04833374 (ClinicalTrials.gov)	May 24, 2021	4/4/2021	Steroids Therapy in IgA Nephropathy With Crescents	Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Crescents : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.	IgA Nephropathy	Drug: Methylprednisolone	Sixth Affiliated Hospital, Sun Yat-sen University	NULL	Recruiting	14 Years	65 Years	All	200	Phase 3	China
2	EUCTR2016-004507-31-FR (EUCTR)	27/01/2017	02/02/2017	N/A	N/A - TIGER	MedDRA version: 19.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders	Trade Name: METHYLPREDNISOLONE MYLAN Générique Product Name: METHYLPREDNISOLONE MYLAN Générique INN or Proposed INN: Methylprednisolone Other descriptive name: Methylprednisolone Trade Name: PREDNISONE ARROW 20mg Product Name: PREDNISONE ARROW 20mg INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Trade Name: PREDNISONE ARROW 5 mg Product Name: PREDNISONE ARROW 5 mg INN or Proposed INN: Prednisone 5 mg Other descriptive name: Prednisone 5 mg	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	122	Phase 3	France
3	NCT02647255 (ClinicalTrials.gov)	March 2016	21/12/2015	Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy	Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)	Glomerulonephritis, IGA;Kidney Diseases;Acute Renal Insufficiency;Rapidly Progressive Glomerulonephritis	Procedure: Plasma Exchange (PE);Drug: Methylprednisolone pulse	Peking University First Hospital	NULL	Terminated	14 Years	65 Years	All	10	Phase 2/Phase 3	China
4	NCT02160132 (ClinicalTrials.gov)	June 2014	3/6/2014	A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.	Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.	Glomerulonephritis, IGA;Peripapillary Crescent;Necrosis;Steroid Nephropathy	Drug: Methylprednisolone(intravenously in the 1st-2nd-3rd month );Drug: Methylprednisolone(intravenously in the 1st-3rd-5th month)	Sun Yat-sen University	NULL	Recruiting	14 Years	65 Years	Both	180	Phase 2	China
5	NCT01560052 (ClinicalTrials.gov)	May 5, 2012	15/3/2012	Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)	Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study Low Dose Study	IgA Glomerulonephritis	Drug: methylprednisolone;Drug: Placebo	The George Institute	Peking University First Hospital	Completed	18 Years	N/A	All	503	N/A	Australia;Canada;China;Hong Kong;India;Malaysia
6	ChiCTR-TRC-09000607	2008-12-01	2009-11-28	Observation for Efficacy of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathy	Efficacy Observation of methylprednisolone and combined therapy of methylprednisolone and mycophenolate mofetil for IgA nephropathy	IgA nephropathy	A:Methylprednisolone 0.4mg/kg * 8 weeks, reduction to 5mg / d to maintain, MMF 0.75 bid * 6 months after the reduction (weight <50kg, MMF0.5 bid);B:ethylprednisolone 0.4mg/kg*8 weeks, reduction to 5mg / d to maintain;	Zhongshan Hospital of Fudan University	NULL	Completed	18	70	Both	A:40;B:40;		China
7	EUCTR2007-000871-41-DE (EUCTR)	24/01/2008	27/11/2007	Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAN	Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAN	IgA nephropathy (IgAN) as the most common type of glomerulonephritis. MedDRA version: 16.1;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders	Product Name: Azathioprine INN or Proposed INN: AZATHIOPRINE Product Name: Cyclophosphamid INN or Proposed INN: CYCLOPHOSPHAMIDE Product Name: Prednisolon INN or Proposed INN: PREDNISOLONE Product Name: Methylprednisolon INN or Proposed INN: METHYLPREDNISOLONE Product Name: supportive therapy	RWTH Aachen	NULL	Not Recruiting			Female: yes Male: yes	148		Germany
8	NCT00657059 (ClinicalTrials.gov)	September 2007	8/4/2008	Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)	A Prospective, Multicenter, Randomized Controlled Trial of Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)	IgA Nephropathy	Drug: irbesartan;Drug: methylprednisolone (MP) or prednisone (pred);Drug: mycophenolate mofetil (MMF)	Sun Yat-sen University	NULL	Completed	14 Years	60 Years	All	151	Phase 3	China
9	JPRN-UMIN000000593	2006/11/01	05/02/2007	Randomized controlled trial of mizoribine for progressive IgA nephropathy	Randomized controlled trial of mizoribine for progressive IgA nephropathy - Randomized controlled trial of mizoribine for progressive IgA nephropathy	IgA nephropathy with moderate to severe histological alterations	Methylprednisolone pulse therapy followed by oral prednisolone administration Methylprednisolone pulse therapy followed by oral prednisolone and mizoribine administration	West Japan Study Group for Therapy of IgA Nephropathy	NULL	Complete: follow-up complete	15years-old	60years-old	Male and Female	120	Not selected	Japan
10	NCT01392833 (ClinicalTrials.gov)	December 1999	5/7/2011	Steroids and Azathioprine in Advanced IgAN	Steroids and Azathioprine in Early and Advanced IgA Nephropathy: Amendments to a Prospective Randomised Multicenter Trial	IgA Nephropathy;Chronic Kidney Disease	Drug: methylprednisolone;Drug: azathioprine;Drug: prednisone	A. Manzoni Hospital	NULL	Completed	16 Years	70 Years	Both	46	Phase 3	NULL
11	NCT00367562 (ClinicalTrials.gov)	January 1996	22/8/2006	Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephropathy	Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy	IGA Nephropathy	Drug: ENALAPRIL VALSARTAN METHYLPREDNISONE	Hospital Britanico	NULL	Completed	21 Years	70 Years	Both	20	Phase 4	Argentina

先頭へ

83. アジソン病

臨床試験数 : 20 / 薬物数 : 39 - (DrugBank : 13) / 標的遺伝子数 : 6 - 標的パスウェイ数 : 18

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-001682-33-GB (EUCTR)	06/09/2012	15/06/2012	Rescue of Addison’s disease 2	Combined Immunotherapy and Trophic Adrenocortical Stimulation in New Onset Autoimmune Addison’s Disease - Rescue of Addison’s disease 2 (RADS2)	Autoimmune Addison's disease: autoimmune primary adrenal insufficiency MedDRA version: 16.1;Level: PT;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders MedDRA version: 16.1;Level: LLT;Classification code 10001335;Term: Adrenal cortex insufficiency;Classification code 10001342;Term: Adrenal cortical hypofunction;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Mabthera infusion Product Name: Mabthera Infusion Product Code: Rituximab Trade Name: Solu-Medrone Product Name: Solu-Medrone Product Code: Methylprednisolone Trade Name: Synacthen Depot Product Name: Synacthen Depot Product Code: Tetracosactide acetate	Newcastle upon Tyne Hospitals NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	30	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom

84. サルコイドーシス

臨床試験数 : 149 / 薬物数 : 202 - (DrugBank : 78) / 標的遺伝子数 : 66 - 標的パスウェイ数 : 169

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01652417 (ClinicalTrials.gov)	October 2012	16/5/2012	Treatment of Renal Sarcoidosis by Methylprednisolone Bolus	Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis	Renal Sarcoidosis	Drug: methylprednisolone bolus IV 15 mg/kg/d for 3 days.	Assistance Publique - Hôpitaux de Paris	NULL	Terminated	18 Years	N/A	Both	40	N/A	France

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200058688	2022-07-01	2022-04-14	A prospective, single-center, randomized controlled trial of glucocorticoid impulse therapy for acute exacerbation of idiopathic pulmonary fibrosis	A prospective, single-center, randomized controlled trial of glucocorticoid impulse therapy for acute exacerbation of idiopathic pulmonary fibrosis	Acute exacerbation of idiopathic pulmonary fibrosis	Glucocorticoid impulse therapy group:Methylprednisolone 500mg/qd intravenous for 3 days;High dose glucocorticoid control group:Methylprednisolone 160mg/qd intravenous for 3 days,then taped gradually.;	Nanjing Drum Tower Hospital, The Affiliated Nanjing University Medical School	NULL	Pending			Both	Glucocorticoid impulse therapy group:30;High dose glucocorticoid control group:30;	N/A	China

86. 肺動脈性肺高血圧症

臨床試験数 : 1,205 / 薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01086540 (ClinicalTrials.gov)	June 24, 2011	11/3/2010	Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)	A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)	Systemic Sclerosis-Associated PAH	Biological: Rituximab;Other: Placebo;Diagnostic Test: CMRI;Drug: prednisone;Drug: methylprednisolone;Drug: diphenhydramine;Drug: acetaminophen	National Institute of Allergy and Infectious Diseases (NIAID)	Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc.	Completed	18 Years	75 Years	All	57	Phase 2	United States

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04933292 (ClinicalTrials.gov)	June 16, 2021	1/5/2020	A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome	A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome	Autoimmune Hepatitis;Primary Biliary Cirrhosis	Drug: Methylprednisolone and Mycophenolate mofetil;Drug: Methylprednisolone and azathioprine	Xiaoli Fan	NULL	Recruiting	18 Years	70 Years	All	78	Phase 4	China
2	NCT04617561 (ClinicalTrials.gov)	November 1, 2020	29/10/2020	Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II	Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II:A Randomized Controlled Open-label Clinical Trial	Hepatitis, Autoimmune;Primary Biliary Cholangitis	Drug: Ursodeoxycholic acid;Drug: Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)	West China Hospital	NULL	Recruiting	18 Years	70 Years	All	90	Phase 4	China

95. 自己免疫性肝炎

臨床試験数 : 52 / 薬物数 : 68 - (DrugBank : 27) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04933292 (ClinicalTrials.gov)	June 16, 2021	1/5/2020	A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome	A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome	Autoimmune Hepatitis;Primary Biliary Cirrhosis	Drug: Methylprednisolone and Mycophenolate mofetil;Drug: Methylprednisolone and azathioprine	Xiaoli Fan	NULL	Recruiting	18 Years	70 Years	All	78	Phase 4	China

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05587673 (ClinicalTrials.gov)	October 6, 2022	14/10/2022	High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)	A Pilot Study Investigating the Feasibility and Efficacy of Locoregional Intra-arterial Administration of Methylprednisolone as a Bridge Therapy to Treat Symptomatic Flares in Inflammatory Bowel Disease.	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Indeterminate Colitis	Drug: Methylprednisolone	Stanford University	NULL	Recruiting	4 Years	25 Years	All	30	Phase 1	United States
2	NCT04224558 (ClinicalTrials.gov)	December 15, 2020	4/4/2018	Stem Cell Transplantation in Crohn's Disease	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease	Crohn Disease	Drug: Mesna;Drug: Cyclophosphamide;Drug: Filgrastim;Procedure: Apheresis catheter placement;Procedure: Leukapheresis;Drug: Fludarabine;Drug: Methylprednisolone;Drug: Diphenhydramine;Drug: Acetaminophen;Drug: anti-thymocyte globulin (rabbit);Drug: lymphocyte immune globulin;Biological: Peripheral Blood Stem Cell Infusion;Drug: Cytoxan	Cedars-Sinai Medical Center	NULL	Recruiting	13 Years	28 Years	All	15	Phase 1/Phase 2	United States
3	NCT03219359 (ClinicalTrials.gov)	July 12, 2017	13/7/2017	Autologous Stem Cell Transplant for Crohn's Disease	Maintenance in Autologous Stem Cell Transplant for Crohn's Disease (MASCT - CD)	Crohn Disease	Procedure: Autologous stem cell transplant;Drug: Cyclophosphamide;Drug: Thymoglobulin;Drug: Methylprednisolone;Drug: Vedolizumab	Aaron Etra	NULL	Recruiting	18 Years	N/A	All	50	Phase 2	United States
4	NCT00554710 (ClinicalTrials.gov)	May 2001	6/11/2007	Top Down Versus Step Up Strategies in Crohn's Disease	The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux	Crohn's Disease	Drug: infliximab+azathioprine;Drug: methylprednisolone or budesonide	Belgian IBD Research Group	Centocor BV;Schering-Plough	Completed	16 Years	75 Years	Both	129	Phase 4	Belgium

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05587673 (ClinicalTrials.gov)	October 6, 2022	14/10/2022	High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)	A Pilot Study Investigating the Feasibility and Efficacy of Locoregional Intra-arterial Administration of Methylprednisolone as a Bridge Therapy to Treat Symptomatic Flares in Inflammatory Bowel Disease.	Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis;Indeterminate Colitis	Drug: Methylprednisolone	Stanford University	NULL	Recruiting	4 Years	25 Years	All	30	Phase 1	United States
2	NCT02921555 (ClinicalTrials.gov)	October 11, 2018	22/9/2016	Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis	Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis.	Ulcerative Colitis	Drug: Methylprednisolone;Drug: Prednisone	Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa	NULL	Completed	18 Years	N/A	All	75	Phase 4	Spain
3	EUCTR2016-001170-15-ES (EUCTR)	19/10/2017	02/08/2017	Intravenous corticosteroids in moderate ulcerative colitis	Efficacy of high-dose corticosteroid pulses added to conventional oral corticosteroid course in comparison with monotherapy oral corticosteroid course for moderate flares of ulcerative colitis: a randomized multicentre clinical trial - CECUM	Moderate flares of Ulcerative Colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Urbason INN or Proposed INN: methylprednisolone Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE	GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis ulcerosa)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	148	Phase 4	Spain
4	NCT01941589 (ClinicalTrials.gov)	September 2013	30/8/2013	Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis	Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.	Ulcerative Colitis	Drug: oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;Drug: corticosteroids only	Sheba Medical Center	NULL	Completed	18 Years	N/A	All	149	Phase 4	China;France;Greece;Israel;Italy;Korea, Republic of;Serbia
5	EUCTR2006-005299-42-BE (EUCTR)	20/05/2008	07/03/2008	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	- Diagnosis of UC according to Lennard-Jones criteria - Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally.- Severe acute flare of UC with a Lichtiger Index score > 10.- Refractoriness to high dose intravenous steroid therapy (= 0.8 mg/kg/d of methylprednisolone or equivalent) given for at least 5 days. MedDRA version: 9.1;Level: LLT;Classification code 10045282;Term: UC	Trade Name: REMICADE INN or Proposed INN: INFLIXIMAB INN or Proposed INN: CICLOSPORIN Other descriptive name: SANDINUM INN or Proposed INN: CICLOSPORIN Other descriptive name: NEORAL Trade Name: CYCLOSPORIN Trade Name: CYCLOSPORIN	GETAID	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100		Finland;Belgium;France;Spain
6	EUCTR2006-005299-42-FR (EUCTR)	16/05/2007	06/03/2007	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	A randomized, multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis (CYSIF Study) - CYSIF	- Diagnosis of UC according to Lennard-Jones criteria - Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally.- Severe acute flare of UC with a Lichtiger Index score > 10.- Refractoriness to high dose intravenous steroid therapy (= 0.8 mg/kg/d of methylprednisolone or equivalent) given for at least 5 days. MedDRA version: 9.1;Level: LLT;Classification code 10045282;Term: UC	Trade Name: REMICADE INN or Proposed INN: INFLIXIMAB INN or Proposed INN: CICLOSPORIN Other descriptive name: SANDINUM INN or Proposed INN: CICLOSPORIN Other descriptive name: NEORAL Trade Name: CYCLOSPORIN Trade Name: CYCLOSPORIN	GETAID	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100		Finland;Belgium;France;Spain

先頭へ

145. ウエスト症候群

臨床試験数 : 43 / 薬物数 : 52 - (DrugBank : 15) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 26

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03876444 (ClinicalTrials.gov)	April 1, 2019	12/3/2019	Intravenous Methylprednisolone Versus Oral Prednisolone for Infantile Spasms	Intravenous Methylprednisolone Versus High Dose Oral Prednisolone for the Treatment of Infantile Spasms: a Randomized Open-labelled Trial	Infantile Spasm	Drug: Intravenous Methylprednisolone;Drug: Oral Pednisolone	Suvasini Sharma	NULL	Recruiting	4 Months	30 Months	All	128	Phase 2/Phase 3	India

162. 類天疱瘡（後天性表皮水疱症を含む。）

臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000029007	2020-01-01	2020-01-11	Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid	Clinical observation of subclinical dosage of cyclosporine combined with glucocorticoid in the treatment of moderate and severe bullous pemphigoid	Bullous Pemphigoid	experimental group:subclinical dosage of Cyclosporine, Prednisone or Methylprednisolone and Halometasone Cream.;control group:Prednisone or Methylprednisolone, Halometasone Cream;	The First Affiliated Hospital of Kunming Medical University	NULL	Recruiting			Both	experimental group:30;control group:30;	Phase 4	China
2	EUCTR2005-002391-14-GB (EUCTR)	29/09/2005	23/08/2005	Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid	Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study - IVMP for ocular pemphigoid	ocular mucous membrane pemphigoid	Trade Name: Solu-Medrone	Moorfields Eye Hospital NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	20	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom
3	NCT00431119 (ClinicalTrials.gov)	October 1997	2/2/2007	Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid	A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid	Bullous Pemphigoid	Drug: Azathioprine or Mycophenolate mofetil	University Hospital Muenster	Hoffmann-La Roche	Completed	18 Years	90 Years	Both	70	Phase 2	Germany

164. 眼皮膚白皮症

臨床試験数 : 15 / 薬物数 : 54 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 141

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00006054 (ClinicalTrials.gov)	March 2000	5/7/2000	Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies		Immunologic Deficiency Syndromes;Chediak-Higashi Syndrome;Common Variable Immunodeficiency;Graft Versus Host Disease;X-Linked Lymphoproliferative Syndrome;Familial Erythrophagocytic Lymphohistiocytosis;Hemophagocytic Lymphohistiocytosis;X-linked Agammaglobulinemia;Wiskott-Aldrich Syndrome;Chronic Granulomatous Disease;X-linked Hyper IgM Syndrome;Severe Combined Immunodeficiency;Leukocyte Adhesion Deficiency Syndrome;Virus-Associated Hemophagocytic Syndrome	Drug: anti-thymocyte globulin;Drug: busulfan;Drug: cyclophosphamide;Drug: cyclosporine;Drug: etoposide;Drug: methotrexate;Drug: methylprednisolone;Drug: prednisone;Procedure: Allogeneic Bone Marrow Transplantation	Fairview University Medical Center	NULL	Terminated	N/A	35 Years	Both		N/A	United States

211. 左心低形成症候群

臨床試験数 : 22 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 14

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2008-007413-76-FI (EUCTR)	27/02/2009	23/12/2008	Metyyliprednisolonin farmakokinetiikka ja -dynamiikka lasten avosydänleikkausten yhteydessä	Metyyliprednisolonin farmakokinetiikka ja -dynamiikka lasten avosydänleikkausten yhteydessä	Lasten ja nuorten sairaalassa (HUS) hoidettavat 1-12 kk ikäiset avosydänleikkaukseen tulevat potilaat, joilla on sydänvikanan TOF, AVSD tai VSD.Lasten ja nuorten sairaalassa (HUS) hoidettavat korkeintaan 28 päivän ikäiset avosydänleikkaukseen tulevat potilaat, joilla on sydänvikana TGA, HLHS tai IAA. MedDRA version: 9.1;Level: LLT;Classification code 10010495;Term: Congenital heart disease NOS	Trade Name: Solu-Medrol INN or Proposed INN: metyyliprednisoloninatriumsuksinaatti Other descriptive name: METHYLPREDNISOLONE SODIUM SUCCINATE	Pertti Suominen	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	105		Finland

220. 急速進行性糸球体腎炎

臨床試験数 : 2 / 薬物数 : 4 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02647255 (ClinicalTrials.gov)	March 2016	21/12/2015	Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy	Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)	Glomerulonephritis, IGA;Kidney Diseases;Acute Renal Insufficiency;Rapidly Progressive Glomerulonephritis	Procedure: Plasma Exchange (PE);Drug: Methylprednisolone pulse	Peking University First Hospital	NULL	Terminated	14 Years	65 Years	All	10	Phase 2/Phase 3	China

222. 一次性ネフローゼ症候群

臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04629248 (ClinicalTrials.gov)	June 25, 2021	27/10/2020	A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy	A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy	Primary Membranous Nephropathy	Drug: Obinutuzumab;Drug: Tacrolimus;Drug: Methylprednisolone;Drug: Acetaminophen;Drug: Diphenhydramine	Hoffmann-La Roche	NULL	Recruiting	18 Years	75 Years	All	140	Phase 3	United States;Argentina;Brazil;China;France;Israel;Italy;Poland;Russian Federation;Spain;Turkey;Ukraine;Peru
2	NCT03466801 (ClinicalTrials.gov)	March 20, 2018	13/1/2018	The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.	The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I.	Idiopathic Membranous Nephropathy	Drug: Prednisone;Drug: MP and CTX	Wenhu Liu	NULL	Terminated	18 Years	80 Years	All	6	N/A	China
3	EUCTR2013-000226-55-NL (EUCTR)	04/03/2015	24/06/2014	SEQUENTIAL THERAPY WITH TACROLIMUS AND RITUXIMAB IN PRIMARY MEMBRANOUS NEPHROPATHY	European Multicenter and Open-Label Controlled Randomized Trial to evaluate the Efficacy of Sequential Treatment with Tacrolimus-Rituximab versus Steroids plus Cyclophosphamide in patientes with Primary Membranous Nephropathy - STARMEN	Primary membranous nephropathy MedDRA version: 17.0;Level: LLT;Classification code 10027170;Term: Membranous nephropathy;System Organ Class: 100000004857;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]	Trade Name: Tacrolimus Product Name: TACROLIMUS INN or Proposed INN: TACROLIMUS Other descriptive name: TACROLIMUS Trade Name: MabThera Product Name: Rituximab INN or Proposed INN: RITUXIMAB Trade Name: Methylprednisolone Product Name: Methylprednisolone INN or Proposed INN: methylprednisolone Other descriptive name: METHYLPREDNISOLONE Trade Name: Prednisolone Product Name: Prednisolone INN or Proposed INN: prednisolone Other descriptive name: PREDNISOLONE ACETATE Trade Name: cyclophosphamide Product Name: cyclophosphamide INN or Proposed INN: CYCLOPHOSPHAMIDE	Fundacion Renal Iñigo Alvarez Toledo	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	175		Spain;Netherlands
4	NCT01955187 (ClinicalTrials.gov)	January 2014	19/9/2013	Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy	European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)	MEMBRANOUS NEPHROPATHY	Drug: TACROLIMUS;Drug: RITUXIMAB;Drug: METHYLPREDNISOLONE;Drug: CYCLOPHOSPHAMIDE	Hospital Universitario 12 de Octubre	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz;Hospital Universitario Fundación Alcorcón;Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre;Biobanco REDinREN;ERA-EDTA;REDinREN;Sociedad Española de Nefrología;Fundación de Investigación Biomédica - Hospital Universitario de La Princesa;University Hospital, Aachen	Completed	18 Years	N/A	All	86	Phase 3	Spain
5	NCT03018535 (ClinicalTrials.gov)	January 2012	9/1/2017	Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	Glomerulonephritis, Membranous	Drug: Rituximab;Drug: Methylprednisolone;Drug: Cyclophosphamide	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	University of Bari;Azienda Ospedaliera Brotzu;University of Messina;University of Milan;Universita di Verona;University of Chieti;University of Bologna;Azienda Sanitaria Locale Roma E;Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi;Regione Piemonte;University of Modena and Reggio Emilia;University of Pisa;University of Milano Bicocca;Humanitas Hospital, Italy;Azienda Ospedaliera Universitaria Policlinico;Fondazione Salvatore Maugeri;University of Bern;University of Alberta;Istituto Giannina Gaslini	Active, not recruiting	18 Years	N/A	All	76	Phase 3	Italy
6	ChiCTR-TRC-11001454	2011-08-01	2011-08-08	Tacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trial	Tacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trial	minimal change disease in adults;ICD10:N04.001	Group A:Tacrolimus orally taken 0.5-1mg q12h for 36w, tape;Group B:prednisone orally taken for 36w, 1.0 mg/kg.d, tape;	Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University	NULL	Completed			Both	Group A:60;Group B:60;		China
7	ChiCTR-ONC-12002809	2009-01-01	2012-05-24	Clinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic Syndrome	Clinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic Syndrome	Idiopathic nephrotic syndrome	1:Given methylprednisolone according to the status of the patients ;	The First Affiliated Hospital of Dalian Medical University	NULL	Completed	18	75	Both	1:90;		China
8	ChiCTR1900022518	2004-04-01	2019-04-15	Clinical trial for corticosteroids monotherapy in the treatment of seronegative hepatitis B virus-associated membranous nephropathy.	Efficacy and safety of corticosteroids in 26 cases of seronegative hepatitis B virus-associated membranous nephropathy	Seronegative Hepatitis B Virus-associated Membranous Nephropathy	Case series:give corticosteroids(Methylprednisolone);	Tianjin Hospital	NULL	Completed			Both	Case series:26;		China
9	NCT00135967 (ClinicalTrials.gov)	May 2002	25/8/2005	Mycophenolate Mofetil in Membranous Nephropathy	Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study	Glomerulonephritis, Membranous	Drug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9	Radboud University	Hoffmann-La Roche	Completed	18 Years	75 Years	Both	30	Phase 2/Phase 3	Netherlands

先頭へ

224. 紫斑病性腎炎

臨床試験数 : 16 / 薬物数 : 43 - (DrugBank : 21) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 58

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02532777 (ClinicalTrials.gov)	August 2015	20/8/2015	The Research of Standard Diagnosis and Treatment for HSPN in Children	The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children	Henoch-Schoenlein Purpura Nephritis	Drug: Prednisone;Drug: Cyclophosphamide(CTX);Drug: Mycophenolate mofetil(MMF);Drug: Leflunomide(LEF);Drug: Angiotensin-converting enzyme inhibitor(ACEI);Drug: Methylprednisolone	Nanjing Children's Hospital	NULL	Recruiting	2 Years	16 Years	All	100	Phase 2	China

271. 強直性脊椎炎

臨床試験数 : 574 / 薬物数 : 359 - (DrugBank : 68) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01790022 (ClinicalTrials.gov)	July 2012	9/2/2013	Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)	Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study	Ankylosing Spondylitis	Drug: Methylprednisolone	Saratov State Medical University	Charite University, Berlin, Germany	Active, not recruiting	18 Years	N/A	Both	20	Phase 2	Russian Federation

283. 後天性赤芽球癆

臨床試験数 : 19 / 薬物数 : 36 - (DrugBank : 23) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00006055 (ClinicalTrials.gov)	March 2000	5/7/2000	Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases		Purpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu Arteritis	Drug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell Transplantation	Fairview University Medical Center	NULL	Active, not recruiting	1 Year	55 Years	Both	10	N/A	United States

284. ダイアモンド・ブラックファン貧血

臨床試験数 : 36 / 薬物数 : 95 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00301834 (ClinicalTrials.gov)	January 2005	9/3/2006	Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders	Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia	Congenital Amegakaryocytic Thrombocytopenia;Diamond-blackfan Anemia;Leukemia;Myelodysplastic Syndromes;Severe Congenital Neutropenia	Biological: alemtuzumab;Drug: busulfan;Drug: cyclosporine;Drug: fludarabine phosphate;Drug: methotrexate;Drug: methylprednisolone;Procedure: allogeneic bone marrow transplantation;Procedure: allogeneic hematopoietic stem cell transplantation;Procedure: peripheral blood stem cell transplantation;Procedure: umbilical cord blood transplantation	University of California, San Francisco	National Cancer Institute (NCI)	Completed	N/A	21 Years	All	35	Phase 2	United States
2	NCT00290628 (ClinicalTrials.gov)	October 1999	9/2/2006	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Transplantation of Umbilical Cord Blood From Related and Unrelated Donors	Chronic Myeloproliferative Disorders;Diamond-blackfan Anemia;Fanconi Anemia;Graft Versus Host Disease;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases	Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: melphalan;Drug: methylprednisolone;Drug: mycophenolate mofetil;Procedure: radiation therapy;Procedure: umbilical cord blood transplantation;Drug: anti-thymocyte globulin;Drug: busulfan	Masonic Cancer Center, University of Minnesota	National Cancer Institute (NCI)	Terminated	N/A	45 Years	All	43	N/A	United States

285. ファンコニ貧血

臨床試験数 : 62 / 薬物数 : 93 - (DrugBank : 30) / 標的遺伝子数 : 30 - 標的パスウェイ数 : 144

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03579875 (ClinicalTrials.gov)	November 13, 2018	25/5/2018	T Cell Receptor a/ß TCD HCT in Patients With Fanconi Anemia	T Cell Receptor Alpha/Beta T Cell Depleted (a/ß TCD) Hematopoietic Cell Transplantation in Patients With Fanconi Anemia (FA)	Fanconi Anemia;Severe Aplastic Anemia;Myelodysplastic Syndromes	Drug: Total Body Irradiation (TBI) (Plan 1);Drug: Cyclophosphamide (CY) (Plan 1);Drug: Fludarabine (FLU);Drug: Methylprednisolone (MP);Device: Donor mobilized PBSC infusion;Drug: G-CSF;Drug: Cyclophosphamide (CY) (Plan 2);Drug: Rituximab;Drug: Busulfan	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	65 Years	All	48	Phase 2	United States
2	NCT01331018 (ClinicalTrials.gov)	February 22, 2012	16/3/2011	Gene Therapy for Fanconi Anemia	Gene Transfer for Patients With Fanconi Anemia Complementation Group A (FANCA)	Fanconi Anemia	Procedure: Bone Marrow Aspiration;Biological: Filgrastim;Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells;Other: Laboratory Biomarker Analysis;Procedure: Leukapheresis;Drug: Methylprednisolone;Drug: Plerixafor;Drug: Prednisone	Fred Hutchinson Cancer Center	National Heart, Lung, and Blood Institute (NHLBI);Rocket Pharma Limited	Active, not recruiting	4 Years	N/A	All	3	Phase 1	United States
3	NCT00084695 (ClinicalTrials.gov)	September 2003	10/6/2004	Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases	The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells	Childhood Langerhans Cell Histiocytosis;Fanconi Anemia;Leukemia;Lymphoma;Myelodysplastic Syndromes;Neuroblastoma;Sarcoma;Unspecified Childhood Solid Tumor, Protocol Specific	Biological: anti-thymocyte globulin;Drug: busulfan;Drug: cyclophosphamide;Drug: fludarabine phosphate;Drug: melphalan;Drug: methylprednisolone;Radiation: radiation therapy	Milton S. Hershey Medical Center	NULL	Recruiting	N/A	21 Years	Both	25	Phase 2	United States
4	NCT00258427 (ClinicalTrials.gov)	March 26, 2002	22/11/2005	Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia	Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia MT2002-02	Fanconi Anemia	Biological: anti-thymocyte globulin;Biological: filgrastim;Drug: busulfan;Drug: cyclophosphamide;Drug: fludarabine phosphate;Drug: methylprednisolone;Biological: Hematopoietic stem cell transplantation	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	44 Years	All	14	Phase 2	United States
5	NCT00053989 (ClinicalTrials.gov)	January 29, 2002	5/2/2003	NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders	Non-Myeloablative Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Disorders	Chronic Myeloproliferative Disorders;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases;Fanconi Anemia;Aplastic Anemia	Biological: anti-thymocyte globulin;Biological: graft-versus-tumor induction therapy;Biological: sargramostim;Biological: therapeutic allogeneic lymphocytes;Drug: cyclophosphamide;Drug: fludarabine phosphate;Drug: methylprednisolone;Drug: mycophenolate mofetil;Drug: tacrolimus;Procedure: allogeneic bone marrow transplantation;Procedure: peripheral blood stem cell transplantation;Procedure: umbilical cord blood transplantation	Roswell Park Cancer Institute	NULL	Completed	4 Years	75 Years	All	41	Phase 2	United States
6	NCT00630253 (ClinicalTrials.gov)	February 17, 2000	5/3/2008	Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia	A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia	Fanconi Anemia	Biological: Anti-Thymocyte Globulin;Drug: Cyclophosphamide;Drug: Fludarabine;Procedure: Hematopoietic Stem Cell Transplantation;Drug: Methylprednisolone;Drug: Filgrastim;Drug: Cyclosporine;Drug: Mycophenolate Mofetil	Masonic Cancer Center, University of Minnesota	NULL	Completed	N/A	59 Years	All	31	Phase 1/Phase 2	United States
7	NCT00290628 (ClinicalTrials.gov)	October 1999	9/2/2006	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Transplantation of Umbilical Cord Blood From Related and Unrelated Donors	Chronic Myeloproliferative Disorders;Diamond-blackfan Anemia;Fanconi Anemia;Graft Versus Host Disease;Leukemia;Lymphoma;Multiple Myeloma and Plasma Cell Neoplasm;Myelodysplastic Syndromes;Myelodysplastic/Myeloproliferative Diseases	Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: melphalan;Drug: methylprednisolone;Drug: mycophenolate mofetil;Procedure: radiation therapy;Procedure: umbilical cord blood transplantation;Drug: anti-thymocyte globulin;Drug: busulfan	Masonic Cancer Center, University of Minnesota	National Cancer Institute (NCI)	Terminated	N/A	45 Years	All	43	N/A	United States

先頭へ

296. 胆道閉鎖症

臨床試験数 : 71 / 薬物数 : 70 - (DrugBank : 39) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 60

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TNRC-09000331	2007-01-01	2009-02-11	Intervention and Efficacy Evaluation Study of Combined Modality Therapy in Patients with Biliary Atrisia after Kasai Operationru	Intervention and Efficacy Evaluation Study of Combined Modality Therapy in Patients with Biliary Atrisia after Kasai Operationru	Biliary Atresia	group 1:Given Yinzhihuang with Ligustrazine from the day 3 after operation;group 2:Given Yinzhihuang with placebo from the day 3;group A:Divide two groups according different glucocorticoid, group A is given dexamethasone from the seventh day after operation;group B:Divide two groups according different glucocorticoid, group B is given methylprednisolone from the seventh day after operation;	The First Affiliated Hospital of Sun Yat Sen University	NULL	Completed			Both	group 1:50;group 2:50;group A:50;group B:50;		China

先頭へ